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Chronic lymphocytic leukaemia (CLL) is the most common type of leukaemia. It 
is common in older people and rare in people under 40. CLL is characterised by 
the accumulation of monoclonal CD5+CD23+ B lymphocytes in the blood, bone 
marrow and secondary lymphatic tissues. There are 2 main subtypes of CLL 
based on the IgHV status: Un-mutated CLL (UM-CLL) and Mutated CLL (M-CLL). 
M-CLL leads to good prognosis whereas UM-CLL is the more aggressive form of 
the disease that could lead to Richter syndrome. Prognostics markers for CLL 
are the IgHV mutational status, chromosomal aberrations, CD38 expression and 
ZAP70 expression. Of these 4 prognostic markers, some are very labour 
intensive and not easy to perform on a routine basis, however ZAP70 expression 
has been a reliable predictor for the prognosis of CLL.  
In this study, I investigated the role of ZAP70 in CLL. This was done using P505-
15, a dual selective SYK and ZAP70 inhibitor, to reduce kinase activity of ZAP70. 
This was followed by siRNA knockdown experiments to disentangle effects of 
SYK and ZAP70 and reduce off target effects from other kinases. In addition, to 
better characterise protein interactors of ZAP70, B cell lines expressing both BirA 
ligase as well as ectopic expression of ZAP70 were generated. Then, 
immunoprecipitation of endogenous ZAP70 in patient CLL cells was carried out 
followed by mass spectrometry analysis.  
BCR signalling is known to play a fundamental role in CLL cell survival and 
proliferation. Here, I have shown that P505-15 reduces calcium mobilization, cell 
survival and proliferation in ZAP70 positive CLL cells. Knockdown of ZAP70 
using siRNA in CLL patient cells was achieved, however efficiency varied 
between patients. Knockdown of ZAP70 using siRNA showed no significant 
change in calcium mobilization compared to non specific siRNA. Using the 
ZAP70 knockdown cells, I further investigated changes downstream of the BCR 
signalling pathway. Comparing siZAP70 to siNSC, siZAP70 showed an increase 
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in pAKT levels in CLL cells post anti IgM activation, however no changes in NF-
κB activity were observed.      
Finally, mass spectrometry using BJAB cells and CLL cells positive for ZAP70, 
confirmed the role of ZAP70 in BCR signalling. In addition, it unexpectedly 
unveiled ZAP70’s role in CLL cell migration and it’s potential role in the DNA 
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2-ME  2-Mercaptoethanol 
A                   Alanine 
ABC DLBCL Activated B-cell like diffuse large B cell lymphoma 
AKT  AMP activated protein kinase 
ATM  Ataxia telangiectasia mutated 
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BCL-2            B-cell lymphoma 2   
BCR  B cell receptor 
BIM               BCL-2-interacting mediator of cell death 
BirA  Biotin ligase 
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BTK  Bruton’s tyrosine kinase 
Ca  Calcium  
CD40L CD40 ligand 
CHK1  Checkpoint kinase 1 
CHK2  Checkpoint kinase 2 
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cNLS  Classical nuclear localization signal  
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DOX  Doxycycline 
DSB  Double stranded break 
EDTA  Ethylene diamine tetraacetic acid 
ERK  Extracellular signal regulated kinase 
EV  Empty vector 
F                    Phenylalanine 
FACS  Fluorescence activated cell sorting 
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FBS  Foetal bovine serum  
FITC  Fluorescein isothiocyanate 
GC  Germinal centre 
GCB DLBCL Germinal centre B-cell like diffuse large B cell lymphoma 
GFP  Green fluorescent protein  
GSEA  Gene set enrichment analysis   
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HR  Homologous recombination 
IgD  Immunoglobulin D 
IgM  Immunoglobulin M 
IgHV  Variable region of the immunoglobulin heavy chain 
ITAM  Immunoreceptor tyrosine based activation motifs 
K                   Lysine 
Lck  Lymphocyte specific protein tyrosine kinase 
M-CLL Mutated CLL 
NaCl  Sodium chloride  
NF-κB           Nuclear factor ‘kappa light chain enhancer’ of activated B-cells 
NHEJ  Non homologous end joining  
NSC  Non specific control 
PBMC  Peripheral blood mononuclear cells 
PBS  Phosphate buffered saline 
PCA  Principal component analysis 
PE  Phycoerythrin 
Puro  Puromycin 
RNAi  RNA interference 
siRNA  Small interfering Ribonucleic acid  
SD  Standard deviation 
SDS  Sodium dodecyl sulphate 
TCR  T cell receptor 
UM-CLL Unmutated CLL 
µl  Microliters 
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2.1         B Cell Development  
 
B Lymphocytes originate from haematopoietic precursors in the bone marrow 
(BM). The earliest cell type to differentiate from the haematopoietic progenitor 
cells (HSC) and commit to the B cell lineage is a Pro B cell (Patton, Plumb, & 
Abraham, 2014). Pro B cells in the bone marrow have to generate functional B 
cell receptors. The B cell receptor is composed of 2 parts: Membrane bound 
immunoglobulin molecules of one isotype (IgD, IgM, IgA, IgG or IgE) and a signal 
transduction moiety. The membrane immunoglobulin, also known as antigen 
binding subunit, is composed of two immunoglobulin light chains (IgLs) and two 
immunoglobulin heavy chains (IgHs). Specifically, the antigen binding site is 
composed of three distinct genetic regions: variable (V), diversity (D), and joining 
(J), that undergo a two step DNA recombination process. This is an error prone 
process involving the combinatorial rearrangement of the V,D,J gene segments 
in the heavy chain locus and V,J gene segments in the light chain loci (Nguyen, 
Pawlikowska, Firlej, Rosselli, & Aoufouchi, 2016). These variations result in the 
diverse (>1010) combinations of functional VDJH and VJL rearrangements 
encoding the BCR (Ralph & Matsen, 2016), allowing for the recognition of 
antigens from all types of pathogens including bacteria, parasites, and viruses. 
During this two-step DNA recombination process in the bone marrow, Pro B cells 
undergo rearrangement of immunoglobulin (Ig) heavy chain genes, to become 
pre B cells. Mutations or alterations at the pre B cell stage could result in the 
development of cancer, immunodeficiency or autoimmunity. These cells further 
undergo light chain rearrangement to enable cells to express surface IgM, to 
become immature B lymphocytes. Upon exiting the BM, they enter the peripheral 
blood and start to express IgD to become naive B cells. Further activation by 
antigen presenting cells results in differentiation into plasma cells or memory B 
cells (Figure 1).  
Throughout B cell development, the cells undergo several checkpoints to ensure 
the BCR is functional. Checkpoint 1 occurs after the rearrangement of the 
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functional heavy chain which pairs with the light chain to form pre BCR. 
Successful intracellular signalling events then prompt the B cells to rearrange 
and express the functional light chain. Failure to transduce the pre BCR signal 
results in arrest of further development of the B cell. The second checkpoint in B 
cell development is to test the interaction of BCR with bone marrow derived 
antigens (autoreactivity). Here, the diverse antibody repertoire is generated and 
checks that the BCRs recognise foreign and not self antigens. A vast majority of 
B cells react with self-antigens, resulting in cell death (negative selection), 
however non-reactive BCRs that survive are positively selected to exit the bone 
marrow and enter the peripheral blood.  
In this thesis, I will be focusing on one particular B cell malignancy: Chronic 
Lymphocytic Leukaemia (CLL).   
 
 
Figure 1: Key steps in B cell development: modified from (Ten Hacken, 
Gounari, Ghia, & Burger, 2019). B cell development starts in the bone marrow 
and progresses from haematopoietic stem cells through to pro B, pre B and 
immature pre B cell stages. Pre B cell receptor expression, with IgM heavy chain 





























2.2         B Cell Chronic Lymphocytic Leukaemia (CLL) 
 
2.2.1 Biology and diagnosis of CLL 
 
According to cancer statistics, compiled by CRUK, in 2016 there were 1008 
deaths due to CLL in the UK.  Incidence rate is highest in people between the 
ages of 85-89 (2014-2016), with a higher frequency in males. There has been an 
18% increase in incident rate over time. 
CLL is a very prevalent type of leukaemia due to long survival of CLL patients. 
Leukemic cells build up very slowly over time with minimal symptoms, however 
the accumulation and spread of CLL lymphocytes to other parts including lymph 
nodes, liver and spleen can lead to a symptomatic disease (Rawstron et al., 
2018; Rodrigues et al., 2016).   
       Early diagnosis can be achieved through blood tests showing the presence of at 
least 5,000 B-lymphocytes per microliter in the peripheral blood (Molica et al., 
2014). CLL is known to be a very clinically heterogeneous disease, some 
patients show a prolonged survival while others experience an aggressive form 
of the disease requiring early treatment and suffering from frequent relapse 
(Rassenti et al 2004).  Despite the many promising ongoing research studies, 
CLL has been incurable to date. 
CLL cells arise from both pre and post-germinal centre B lymphocytes (Figure 1) 
and is characterized by the accumulation of monoclonal CD5+CD23+ B 
lymphocytes in the blood, bone marrow and secondary lymphatic tissues 
(Ponader et al., 2012).  Specifically, CLL phenotype is distinctive with leukaemic 
B cells expressing B cell markers such as CD19, low level of CD20 and high 
level of CD23 (Hamblin, Davis, Gardiner, Oscier, & Stevenson, 1999). About 2-
10% of CLL patients develop to Richters syndrome (Parikh, Kay, & Shanafelt, 





2.2.2 Current treatments for CLL/ B Cell immune response  
Over the years, inhibitors such as ibrutinib, idelalisib and venetoclax have been 
used as a choice of treatment for CLL.  
Ibrutinib is a targeted drug that blocks bruton tyrosine kinase protein (BTK). BTK 
plays a main role in B-cell receptor signalling and signals CLL cells to proliferate 
and survive. BTK plays a role in multiple downstream signalling pathways 
including signal transducer and activator of transcription 3 (STAT3) involved in 
pathogenesis of CLL and inducing/sustaining tumour immune tolerance (Kondo 
et al., 2018). 
There are also several oral SYK inhibitors including fostamatinib (R788), 
entospeletinib (GS-9973), and cerdulatinib (PRT062607) being used in clinical 
trials. SYK is a cytosolic non-receptor protein tyrosine kinase (PTK) discovered in 
1990 and expressed in haematopoietic cells. SYK is a critical element in the BCR 
signalling pathway and in cooperation with other BCR signalling molecules, plays 
a vital role in signal transduction independent from the BCR (Liu & Mamorska-
Dyga, 2017). In particular, PRT062607 (also known as P505-15 referred to in this 
thesis) is an oral kinase inhibitor against SYK, and ZAP70. In vitro studies using 
this inhibitor in ABC and GCB lymphoma cell lines induced apoptosis and cell 
cycle arrest. In primary CLL cells, treatment with P505-15 inhibited BCR and IL4 
induced downstream signalling in CLL cells and reduced CCL3/CCL4 
productions (Blunt MD, Koehnrer S, Dobson RC, Larrayoz M, Wilmore S, 
Hayman A, Parnell J, Smith LD, Davies A, Johnson PWM, Conley PB, Pandey A, 









2.2.3 Prognostic Markers of CLL 
Disease prognosis in CLL is extremely variable however abnormality in the 
immunoglobulin heavy chain variable (IgHV) has been used as a prognostic 
marker. However this technique is very laborious, expensive and time consuming 
for most medical centres to carry out as a routine procedure. Therefore, other 
predictors of prognosis and treatment response for CLL patients were sought 
which included expression of CD38 surface marker, level of zeta associated 
protein 70 (ZAP70) (Rassenti et al. 2004) and other chromosomal aberrations 
discussed in detail below.  
 
IgHV mutational status 
CLL patients are classified as: Mutated IgHV (M) or Unmutated IgHV (UM) based 
on the degree of somatic mutations. The criteria for mutated IgHV is greater than 
2% deviation from germ line sequence (Fais et al., 1998).  As mentioned above, 
after antigen engagement, V,D,J gene segments in heavy chain and V, J 
segments in light chain are modified by somatic mutations to higher affinity.  
CLL cells that carry the UM-IgHV likely undergo malignant transformation prior to 
the entry into germinal centres and result in poor prognosis, on the other hand 
CLL cells with the M-IgHV that transit through the germinal centre and then 
undergo final development generally have good prognosis (Hamblin et al., 1999) 
(Figure 1). Both subtypes have similar gene expression patterns, hence it’s been 
suggested that the difference in disease progression is due to BCR signalling 
which is the most important pathway activated in CLL cells in proliferative areas 
within lymphatic tissues (Burger & Chiorazzi, 2013) discussed in detail in section 
2.5. 
        
       Chromosomal aberrations in CLL  
CLL cells are known to carry a number of recurrent genomic aberrations that 
appear during the course of the disease and can be used as another prognostic 
marker.  These aberrations are 13q14 (deletion on the long arm of chromosome 
13, occurring in > 50% of patients), trisomy 12 (10-20% of patients) and 11q22-
q23 deletion (10-20% cases). In regards to disease prognosis, patients with 
17pDEL and 11qDEL experience more aggressive disease, whereas patients 
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with 13qDEL as the only abnormality have an indolent clinical outcome 
(Puiggros, Blanco, & Espinet, 2014; Stilgenbauer, Bullinger, Lichter, & Döhner, 
2002).   
In a few of these aberrations, a molecular target has been identified: in the case 
of 11q22-23 deletion, the ATM (Ataxia telangiectasia mutated) tumour 
suppressor gene is localized at this deleted site (Jiang et al., 2016). This is 
further discussed in section 2.8.3. The other deletions in chromosomal band 
13q14.3 are targeting genes encoding microRNAs miR-15a/16-1. miRNAs are 
short RNAs, between 19-25 nucleotides, that regulate gene expression. Their 
deregulation can alter expression levels of genes involved in the development 
and progression of tumours. CLL patients with various IgHV and ZAP70 kinase 
status have shown a unique miRNA signature in miR-15/16, miR-29 and miR-155 
and are composed of the most frequently deregulated miRNAs in the various 
malignancies. Particularly, miR-29 was found to be down regulated in CLL and a 
strong predictor of aggressive disease (Stamatopoulos et al., 2009). In addition, it 
was found that miR-21 expression stratifies survival of patients with 17pDEL 
(Rossi et al., 2010). Aberrations in chromosome 17 and the p53 mutations (17p 
13.1) play vital roles in the pathogenesis of CLL. The gene p53 is a tumour 
suppressor, mutations in this gene result in an aggressive CLL disease with rapid 
progression and poor prognosis with low survival in the patients (Lens et al., 
1997).  
This feature of chromosomal aberrations is associated with the DNA damage 
response (DDR) pathway and dysregulation of the cell cycle. CLL progression is 
greatly affected by defects in DDR pathway and interacting cells in the 
microenvironment. Sequencing studies have identified somatic gene mutations in 
TP53, ATM, CHK1, CHK2, and BRCA1 in CLL patients, which are all involved in 
the DDR pathway explained in detail in section 2.8. 
  
CD38 surface marker  
CD38 is considered to be a reliable marker of unfavourable prognosis in CLL. B 
lineage progenitors in the BM, B-lymphocytes in the germinal centre, activated 
tonsils and terminally differentiated plasma cells all express high levels of CD38. 
However, memory B cells express low levels of CD38. CD38 is an integral 
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surface marker and known to localize in membrane lipid microdomains in close 
proximity with the BCR complex (CD19/CD81) and with molecules regulating 
homing (CXCR4 and CD49d). The threshold of CD38 positivity in CLL cells is >= 
30% to be considered positive.  Increased CD38+ve clones are more responsive 
to BCR signalling in vitro (Malavasi et al., 2011). In addition, Vaisitti et al, showed 
an association between CD38 and migratory behaviour of CLL cells, and a direct 




Another important prognostic marker in CLL is ZAP70 expression. Wiestner, A. et 
al have elegantly shown using a cohort of 107 patients that ZAP70 gene 
expression can be used to distinguish the UM-CLL and M-CLL subtypes. UM-
CLL cells expressed 5.54 fold more ZAP70 compared to the M-CLL, which 
correctly predicted the IgHV status in 93% of the patients (Wiestner, 2003). 
Similarly, the majority of leukaemic cells without IgHV mutations expressed high 
levels of ZAP70, whereas leukaemic cells with IgHV mutations had very low 
levels of ZAP70 (Crespo et al., 2003). In addition it’s been shown by flow 
cytometric analysis that ZAP70 expression alone can be used as a prognostic 
marker using the 20% cut off for ZAP70 positive B cells criteria and giving a 
simple and reliable surrogate marker for the identification of IgHV mutations. 
However, based on large cohort data, quantitative ZAP70 and CD38 expressions 
cannot replace IgVH analysis but in contrary addition of quantitative data can 
further specify prognoses of patients with CLL.  
As shown in Figure 2, lower expression of ZAP-70 is associated with better 




               
Figure 2: Relationship between ZAP70 expression level and the time from 
diagnosis to initial therapy (Rassenti et al. 2004). CLL cells with ZAP70 
expression ≤ 10% had median times from diagnosis to initial treatment as 9.2 
years, which was not significantly different from CLL patients with ≥ 10% but ≤ 
20%. Similarly two patient cohorts, ≥20 to ≤30% and >30%, had a median 
survival time of 3 years from diagnosis to initial therapy. 
 
2.3         ZAP70  Zeta chain associated protein kinase 70 
 
2.3.1 Discovery of ZAP70 
  
ZAP70 is a SYK related tyrosine kinase first identified in T Cell Receptor (TCR) 
stimulated Jurkat cells (Chan et al. 1991). ZAP70 is expressed in T cells and 
Natural killer (NK) cells and is important for proximal TCR and NK cell signalling 
(Chan et al. 1992). Studies have shown that ZAP70 is expressed in CLL B cells 
(Chen et al. 2008) and expression of ZAP70 (> or =20% of B cells by flow 
cytometry) has been associated with an increased risk for an adverse outcome in 
B CLL cells and is considered an important risk factor in these patients. ZAP70 is 
highly homologous to SYK, hence defined as a member of the SYK/ZAP70 
kinase family (Taniguchi et al., 1991). Specifically, amino acid sequence 
comparison between ZAP70 and porcine SYK revealed a 60 amino acid 
divergent region between the SH2(C) and the kinase domains (residues 248-308 
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in ZAP70 and residues 247-334 in porcine SYK) that includes a 26 amino acid 
insertion in SYK not present in ZAP70. Similarly an additional 17 amino acid C 
terminal extension is present in ZAP70 and absent in SYK. These changes were 
suggested to mediate specific interactions of ZAP70/SYK with effectors upstream 
or downstream (Andrew C. Chan, Iwashima, Turck, & Weiss, 1992).  
The ZAP70 gene is located on chromosome 2q11.2 and is composed of 14 
exons. ZAP70 is composed of two N terminal SH2 domains and a C terminal 
kinase domain. There are also 2 linker domains: Interdomain A which connects 
both SH2 domains, and interdomain B that connects the SH2 domain to the 
kinase domain (Figure 3). The SH2 domain plays an important role in double 
phosphorylation of the immunoreceptor tyrosine based activation motif (ITAM) 
and Interdomain B contains many tyrosine residues that aid in regulating the 
ZAP70 kinase activity. Specifically, Interdomain B contains three tyrosine 
residues: Y292, Y315 and Y319 which when phosphorylated by lymphocyte 
specific protein tyrosine kinase (Lck) upon TCR activation serve as docking sites 
for downstream signalling molecules (H. Wang et al., 2010). These tyrosine 
residues are explained in detail in section 2.4.1.  The kinase domain of ZAP70 
contains a conserved region similar to other protein tyrosine kinases. Specifically, 
there is 38% amino acid identity with abl and the src family PTKs (Andrew C. 
Chan et al., 1992). Major differences between ZAP70 and src family PTKs are 
that ZAP70 lacks a negative regulatory C terminal tyrosine residue and also lacks 
a myristylation site at amino acid 2 but contains a catalytic domain (Andrew C. 
Chan et al.,1992). 
 
Figure 3:  Schematic of ZAP70 domains and phosphorylated tyrosine 
residues modified from (Yan et al., 2013). ZAP70 contains two SH2 domains 
connected by two interdomains (A and B) and a kinase domain. SH2 domains 
are vital for ITAM phosphorylation and Interdomain B contains tyrosine residues 
important for phosphorylation. 
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2.3.2 ZAP70 Localization 
Using a chimeric ZAP70 protein fused to variant GFP expressed in epithelial 
cells, ZAP70 has been shown to be expressed throughout the quiescent cells 
and rapidly recruited to the plasma membrane upon cellular activation of T cells 
(Sloan-Lancaster et al. 1997).  Interestingly, the same group had published that 
ZAP70 resides in the nucleus of quiescent and activated Jurkat T cells. TCRε 
chain plays a major role in the redistribution of ZAP70 enhanced with co-
expression of the active form of LCK (Sloan-Lancaster et al., 1998). Due to the 
large size of the ZAP70 protein, it cannot passively diffuse across the nuclear 
lamina. Therefore presence of nuclear localization signals (NLS) in the protein is 
needed for active transportation across nuclear lamina (unpublished: 
Ringshausen group). Here, using in silico analysis, it was shown clearly that 
ZAP70 carries three potential classical NLS which was confirmed using HELA 
cells transfected with ZAP70 (WT) GFP_ZAP70 wild type, ZAP70 (KA) GFP 
ZAP70 Mutant K369A and various other truncated forms: ZAP70(Trunc1) 
(excludes N terminal SH2), ZAP70(Trunc2) (excludes both SH2), ZAP70(Trunc3) 
excluded whole N terminal except kinase domain, ZAP70 (Trunc 4) (expresses 






                
Figure 4: Potential NLS in ZAP70 predicted by cNLS Mapper (Unpublished: 
Ringshausen group). In silico analysis of potential nuclear localization 
sequence in the ZAP70 amino acid sequence. Established the three N-terminal 
truncation and one C-terminal truncation of the predicted monopartite NLS of 
ZAP70.  
 
Here, HELA cells (non haematopoietic cell line) were used to study ZAP70 
diffusion throughout the cell body (Unpublished: Ringshausen group) (Figure 5) 
and confirms presence of ZAP70 in the cytoplasm as well as nucleus.  
In addition, it was also shown that nuclear ZAP70 upon stimulation via TCR can 
be phosphorylated (Sloan-Lancaster et al 1997).   
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Figure 5: Nuclear translocation of ZAP70 (Unpublished: Ringshausen 
group). Immunofluorescence of HELA cells transfected with 6 different truncated 
versions of ZAP70 using lipofectamine. Trunc 1-3, N-terminal truncated products, 
one C-terminal truncated product and kinase deficient truncated product. Cells 
were counterstained with phalloidin for visualization of the cytoskeleton and with 
DAPI for nuclear depiction.   
 
2.4         ZAP70 signalling in T cells 
 
T lymphocytes (T cells) play a very important role in the cell mediated adaptive 
immune response by providing antigen recognition and cytotoxic reaction 
towards infected cells. T cells originate from haematopoietic stem cells in the 
bone marrow. T cells can be distinguished from other lymphocytes such as B 
cells and NK cells by the presence of the TCR on the cell surface.    
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ZAP70 is essential for normal development of T cells and in TCR signalling. This 
can be seen in ZAP70 deficient patients which have no functional T cells in their 
peripheral blood and suffer from severe combined immunodeficiency (SCID) 
(Elder et al., 1994). In 1994, Arpaia et al had reported that patients with 
mutations in the ZAP70 gene usually had severe T cell deficiencies, specifically 
these mutations were in the catalytic domain of ZAP70. Studies on ZAP70 
deficient mice have shown that T cell development is arrested at the transition 
from double positive (CD4+CD8+) stage, where positive selection occurs 
(Kadlecek et al., 1998).  
In 1991, Chan et al described a model describing TCR signalling mediated by 
ZAP70, in which upon the TCR encountering the peptide antigen bound to MHC 
complex on APC, the co-receptor associated LCK is brought near the CD3 
complex and phosphorylates tyrosines in the ITAMS. When ITAM is doubly 
phosphorylated, ZAP70 is recruited with high affinity by binding to the tandem 
SH2 domains of ZAP70 (Figure 6). In addition, to achieving catalytic activity, the 
tyrosines in the activation loop of ZAP70 are then phosphorylated by LCK or 
ZAP70 itself. There are also other signalling proteins like LAT and SLP76 that 
are recruited in the process. All of these signalling events lead to T cell 




Figure 6: A sequential model for T cell activation modified from (Yan et al., 
2013). TCR encounters the antigen, brings LCK nearer the CD3 complex and 





2.4.1 Roles of Y292, Y315 and Y319 during ZAP70 signalling 
Tyrosine residue at Y292 has a negative regulatory function due to the 
recruitment of E3 ubiquitin ligase c-CBL. Zhao et al reported a negatively 
regulated role of Y292 in interdomain B. Tyrosine residues Y315 and Y319 have 
positive regulatory sites of phosphorylation. Both tyrosine resides become 
phosphorylated post TCR cross-linking by LCK and ZAP70 itself (Williams, 
1999). Mutations of both Y315 and Y319 to phenylalanine (F) can render the 
kinase inactive (Wang et al. 2010). Another important role of interdomain B is 
stabilization of the active conformation and providing docking sites for other 
molecules that control ZAP70 function and downstream signalling (Wang et al. 
2010). Tyrosine residue Y493, which is located in the activation loop of ZAP70, 
and its phosphorylation is important for full kinase activity of ZAP70 (Chan et al. 
1995). Finally, ZAP70 mutation K369, that will be used in this study and referred 
to as KA mutant in this report, is a point mutation that changes lysine (K) to an 
alanine (A) at position 369. This mutation is located in the kinase domain of 
ZAP70 and it renders ZAP70 kinase inactive by preventing ATP binding (at 
position 345 to 352) due to alterations in the catalytic binding site (Johnson et al. 
1996).  
2.4.2     Mechanism of deregulation of ZAP70 
In 2005, studies showed association of ZAP70 expression status in CLL with the 
methylation status of the intron1-exon2 boundary region of ZAP70 (Corcoran et 
al., 2005). Subsequently, in 2010, pyrosequening analysis of ZAP70 methylation 
in CLL uncovered several alternative sites in intron 1 and suggested a correlation 
of methylation with CD38 expression and IGHV mutation status (Chantepie et al., 
2010). In addition, it was shown that ZAP70 promoter is associated with the 
active histone modifications and reduced DNA methylation led to transcriptional 
de-repression of ZAP70, therefore suggesting that expression of ZAP70 in CLL 
cells seems to be epigenetically regulated (Amin et al., 2012). Specifically, 
enrichment of di and tri-methylation of lysine 4 of histone H3 and higher levels of 
global acetylation are associated with the ZAP70 promoter regions in ZAP70 




2.5         BCR signalling  
 
BCR signalling is very important in the pathogenesis of B cell lymphomas and 
has been extensively studied over many years (Herzog, Reth, & Jumaa, 2009). 
The BCR complex is composed of membrane immunoglobulin paired with the 
signal transduction component, Igα-Igβ heterodimers  (CD79A and CD79B). 
Upon activation by an antigen, ITAMs in the cytoplasmic tail of CD79A and 
CD79B are phosphorylated by LYN, and other Src family kinases (Fyn, BLK). 
This results in recruitment of kinases, such as SYK and BTK, and subsequent 
activation of SYK (Rowley, Burkhardt, Chao, Matsueda, & Bolen, 1995).  Further 
association of SYK with adaptor molecule B cell linker protein (BLNK) and its 
downstream signalling components BTK and PLC-γ2 results in B cell selection, 
proliferation, differentiation and antibody production (Moroni et al., 2004; 
Wossning et al., 2006) (Figure 7).  As detailed in the review by Woyach et al, 
2012, SYK causes the double phosphorylation of the CD79A/CD79B complex 
and LYN forms a complex with CD19 and provides continued amplification of the 
BCR. Initial recruitment of kinases/adaptor protein results in BCR activation via 
three main pathways: BTK, PLCϒ2 and PI3K.  BTK self phosphorylates, however 
SYK and LYN leads to phosphorylation of PLCϒ2.  In the phosphorylation of 
PLCϒ2, BLNK is recruited and is rapidly phosphorylated by SYK.  Interaction of 
SYK, BTK, BLNK, and PLCϒ2 further dually phosphorylates PLCϒ2 to produce 
second messengers diacylglycerol (DAG: activator of protein kinase C) and 
inositol-1-4-5 triphophate (IP3) from the plasma membrane lipid 
phosphatidylinositol 4,5-biphosphate (PIP2).  Presence of IP3 causes calcium 
influx from endoplasmic reticulum and extracellular compartment.  This finally 
leads to translocation of NF-κB (nuclear factor “kappa light chain enhancer” of 






Figure 7: B cell receptor signalling pathways modified from (Woyach, 
Johnson, & Byrd, 2012b). Upon antigen activation, ITAM is phosphorylated by 
LYN resulting in the recruitment of BTK and SYK. Phosphorylation of SYK leads 
to recruitment of BLNK and activation of PLCϒ2 and further activation of 
downstream pathways. 
 
2.5.1 BCR signalling in CLL  
Despite the current view that the majority of immature B cells that express 
autoreactive B cell receptors are negatively selected, it has been shown that 
polyreactive BCRs recognize multiple self antigens, induced autonomous 
signalling and selective expansion of B cell precursors in a similar manner to pre 
BCR (Köhler et al., 2008). Autonomous signalling occurs whereby the surrogate 
light chain induces ligand independent pre BCR crosslinking and leads to 
expansion, which is needed for positive selection of B cells.  
In B cell lymphomas, there are two different mechanisms of BCR activation: 
Antigen dependent or ligand independent (“tonic” BCR signalling) resulting in B 
cell selection, proliferation, differentiation and antibody production. Activating 
mutations in the BCR pathway are common in DLBCL, however in CLL, BCR 
pathway activation does not involve activating mutations, hence it is antigen 
dependent (auto antigen or microbial antigens present in the microenvironment), 
which results in the oncogenic transformation and disease progression (Binder et 
al.,2013; Minden et al., 2012). Similarly, functional snapshots of the CLL B cell 
phenotype suggest that CLL cells are aberrantly held in a hyperactive state 
similar to B cells exposed to antigen (Damle et al., 2002). “Tonic” activation was 
suggested due to the observation that phosphorylated LYN, SYK, and ERK were 





















2009). This observation was supported by two key papers in 2012 and 2013 that 
showed an unexpected form of auto reactive BCR activation in CLL. In 2012, 
Duhren et al had shown that by transferring the heavy chain complementarity 
determining region (HCDR3) of a CLL derived BCR provides autonomous 
signalling capacity to a non autonomously active BCR, whereas mutations in the 
internal epitope abolishes this capability (Minden et al., 2012). This was followed 
by a report of an alternative epitope for CLL BCR self-recognition located in the 
FR3 of Igs playing a vital role in BCR signalling in CLL (Binder et al., 2013). 
 
2.6         Effect of ZAP70 expression on BCR signalling in CLL 
 
ZAP70 in the TCR was discovered many years ago, however the presence of 
ZAP70 in B cells is still unclear. ZAP70 plays a vital role in CLL and the presence 
of ZAP70 is strongly correlated with poor clinical outcome (Dürig et al., 2003). 
ZAP70 has been found to be associated with the B-cell receptor signalling in CLL 
(Chen et al. 2002). Furthermore, it has been shown that BCR signalling can be 
reconstituted by ZAP70 in SYK deficient B cells (Toyabe, Watanabe, Harada, 
Karasawa, & Uchiyama, 2001).  
It is important to note that SYK is structurally homologous to ZAP70. BCR 
mediated activation of ZAP70 is very inefficient/ negligible compared to SYK in 
CLL, however the ability of ZAP70 to recruit downstream signalling molecules in 
response to activation is preserved (Stefania Gobessi et al., 2007). This was 
shown using avian lymphoma B cells, where even in the absence of SYK, ZAP70 
was able to restore some BCR signalling events (Stefania Gobessi et al., 2007). 
Furthermore, in CLL B cells, introduction of ZAP70 (adenoviral gene transfer) in 
the presence of SYK, resulted in stronger activation of certain BCR signalling 
molecules including SYK, BLNK and PLCϒ (Pede et al. 2013). Furthermore, 
stronger calcium mobilization was observed in ZAP70 positive CLL cells 
compared to ZAP70 negative cells upon BCR ligation (Chen et al., 2005a). This 
suggests that the function of ZAP70 in CLL cells could be to enhance BCR 
signalling (Wang et al. 2010). Finally, it was reported that ZAP70 positive CLL 
cells showed increased proliferative response and enhanced survival upon TLR9 
stimulation compared to ZAP70 negative cells, suggesting that ZAP70 may 
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operate as an amplifier for TLR9 mediated activation of the BCR signalling 
(Wagner et al., 2016).  
Similar to the importance of BCR signalling in CLL, there are two other vital 
pathways that have an impact on CLL cells: the DNA damage pathway, 
(discussed briefly in the chromosomal aberrations section 2.2.3) and CLL cell 
migration. These 2 aspects and their relation to CLL will be discussed in detail in 
sections 2.8 and 2.9.  
 
2.7             ZAP70 in other B cell neoplastic disorders    
 
As mentioned in section 2.3.1, ZAP70 is expressed in CLL B cells (Chen et al. 
2008) and > or =20% of B cells by flow cytometry have been associated with an 
increased risk for an adverse outcome in B CLL cells and is considered an 
important risk factor in these patients. In addition to CLL, studies using 
immunohistochemistry have characterised ZAP70 expression in other 
hematologic malignant neoplasms. Here, the vast majority of mature B-cell 
neoplasms do not express ZAP-70, however, they have shown that a small 
percentage of DLBCL (diffuse large B-cell lymphoma), MCL (mantle cell 
lymphoma) also express ZAP-70 (Sup et al., 2004). In 2005, another study 
confirmed the results and had assessed ZAP70 expression in a varied spectrum 
of B cell lymphoid neoplasms by immunohistochemistry. Here, the staining was 
compared to flow cytometry and relationship between ZAP70 and mutational 
status was assessed. ZAP70 positivity was obtained in 65% CLL, 31% Burkitts 
lymphoma, 29% lymphoblastic lymphomas, 8% MCL and 4% in marginal zone 
lymphomas and 2% diffuse large B cells lymphomas and absent in 14 samples of 
Hodgkin lymphomas and 19 follicular lymphomas (Carreras et al., 2005).  
2.8         Relationship between CLL and DNA Damage pathway in CLL 
2.8.1 DNA Damage Response Pathway 
The DNA damage response (DDR) pathway functions to detect DNA damage, 
signal its presence, mediate DNA repair and maintain genomic stability (Kastan & 
Bartek, 2004). Both endogenous and exogenous DNA damage results in double 
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stranded breaks (DSB) and cells respond to DSB by activating DDR, which 
includes phosphorylation of the histone H2AX producing γH2AX (Kuo & Yang, 
2008; Podhorecka, Skladanowski, & Bozko, 2010). H2AX is part of the H2A 
family, a component of the histone octomer in nucleosomes. H2AX is 
phosphorylated by two major kinases: ATM/CHK2 and ATR/CHK1 (Ray, Blevins, 
Wani, & Wani, 2016). This process of phosphorylation is the first step in 
recruiting and localizing DNA repair proteins resulting in formation of gamma 
H2AX foci (which is a biomarker for damage). A disturbed DDR plays a vital role 
in promoting CLL cell survival (Frenzel, Reinhardt, & Pallasch, 2016). Discussed 
in the next section are the two DSB repair mechanisms. 
 
2.8.2 DNA double strand break repair 
In mammalian cells, there are 2 major DSB repair mechanisms: error prone non-
homologous end joining (NHEJ) pathway and homologous recombination (HR) 
mediated DSB repair (Arnoult et al., 2017). The NHEJ pathway takes place 
throughout all cell cycle phases and does not depend on an intact DNA 
replication product as a template for repair (Figure 8). NHEJ depends on catalytic 
activity of DNA-PK recruited by non catalytic subunits Ku70 and Ku80 (Wu et al., 
2019a). KU is one part of the DNA-PK related to ATM checkpoint kinase. 
Specifically, NHEJ is a 3-step process: DNA end binding and bridging, terminal 
end processing and ligation. During the first step, NHEJ is initiated by recognition 
and binding of KU proteins to the damaged end. The KU heterodimer forms a 
DNA binding component for DNA-PK and acts to support and align the DNA ends 
to protect from degradation. This leads to recruitment of DNA-PK, serine 
threonine kinases in the PI3K family. DNA-PK phosphorylates DNA ligase IV. If 
ends are incompatible, artemis proteins trim off single stranded overhangs. Blunt 
ends are ligated accordingly (Davis & Chen, 2013).    
On the other hand, HR requires the presence of an intact DNA replication 
product as a template and is an error free DSB repair mechanism (Figure 8). Due 
to its dependence on a template, this repair mechanism is only used in the late S 
and G2 cell cycle phase (Wu et al., 2019b). The HR repair pathway involves 3 
steps: presynapsis, synapsis and post synapsis. During the presynaptic phase, 
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RAD51 is loaded onto single stranded DNA (ssDNA), the RAD51-ssDNA 
(presynaptic filament) comprises of six RAD51 molecules and 18 nucleotides per 
helical turn. During the next phase of synapsis, RAD51 supports the formation of 
a physical connection between invading DNA substrate and homologous duplex 
DNA template leading to formation of D loop.  Here, RAD51-dsDNA filaments are 
formed with the aid of invading and donor ssDNA strands within the filament. 
Finally, post synapsis DNA is synthesized using the invading 3’ end as a primer, 
RAD51 dissociates from dsDNA to expose 3”-OH required for DNA synthesis 
(Krejci, Altmannova, Spirek, & Zhao, 2012). 
 
 
        
       
Figure 8: DNA damage repair mechanisms (modified from (Brandsma & 
Gent, 2012). NHEJ begins with recognition of DNA ends by KU70/80 that recruits 
DNA-PKs. Artemis trims the end if incompatible and ligase seals the break. In HR 
repair pathway, DSB ends are recognised and processed to 3’-OH ending single 
stranded tail. DNA strand invasion by RAD51 generates D loop, invading strand 
is disengaged after DNA synthesis and annealed with the second end (Li & 





2.8.3 ATM/ATR signalling 
As mentioned earlier, initiation of the activities of the PI(3)K kinases, ATM and 
ATR are the first steps to inhibit cell cycle progression after DNA damage. The 
ATM gene maps to chromosome 11q22.q23, within the region that is deleted in 
CLL, resulting in ATM gene inactivation which is associated with defective 
apoptosis in response to chemotherapeutic agents (Guarini et al., 2012). The 
ATM is a nuclear serine/threonine kinase of 350kDa and a member of the PI3K 
family , which are activated in response to DNA double stranded breaks, induced 
by alkylating agents, topoisomerase inhibitors or ionizing radiation. 
ATR is also a very large protein (301KDa) and belongs to the PI3K family, 
however it responds to a broader spectrum of DNA damage. Both ATM and ATR 
activate a second wave of phosphorylation through their activation of CHK1, 
CHK2 protein kinases upon induction due to single stranded breaks or DNA 
lesions (Matsuoka, Huang, & Elledge, 1998). Both ATM and ATR activate the cell 
cycle arresting target genes, DNA repair and apoptosis via p53 activation. 
Studies have shown that patients lacking ATM are unaffected, therefore 
suggesting that it is not essential for critical cellular functions such as normal 
cycle progression or cellular differentiation (Shiloh & Kastan, 2001). In the 
absence of DNA damage, ATM is present as a homodimer in which the kinase 
domain is blocked by its tight binding to an internal domain of the protein 
surrounding serine 1981, a major damage inducible phosphorylation site. Upon 
DSB, ATM undergoes conformational changes that stimulates phosphorylation of 
serine 1981 resulting in dissociation of the homodimer (Bakkenist & Kastan, 
2003) and further phosphorylates p53. 
In CLL, the pro-apoptotic ATM-CHK2-p53 signalling pathway is frequently 
mutationally inactivated through large deletions on chromosome 11q (ATM) or 
17p (TP53) or through protein damaging mutations (Goy et al., 2017) as 
mentioned earlier. Most B-CLL cells undergo apoptotic death in response to DNA 
damage. However, the aggressive subset of B-CLL is completely resistant in vitro 
to irradiation-induced apoptosis (Vallat et al., 2003). Some of the therapies in 
CLL include alkylating agents and the combination of these DNA damaging drugs 
with purine nucleoside analogs. A current treatment option is combination 
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therapy of bendamustine and fludarabine. Results have confirmed that 
combination of both drugs together were synergistic (El-Mabhouh et al., 2014). 
 
2.9         Importance of migration in CLL  
 
2.9.1 Role of chemokines in CLL 
 
Another aspect of CLL that is extensively studied is cell trafficking (Calpe et al., 
2011; Quiroga et al., 2009). CLL cells in the peripheral blood (PB) are arrested in 
the G0/G1 cell cycle stage, and hence do not proliferate in the PB. CLL cell 
proliferation is thought to take place in proliferation centres in the LN and BM. 
Here CLL cells associate with CD40L+/CD4+ T helper cells to aid proliferation. 
Therefore CLL cells ought to migrate from PB to LN/BM (Richardson et al., 
2006). Some of the factors involved are chemokines.  
Chemokines are a family of small proteins (cytokines) secreted either 
constitutively or in response to stimulation by cells and play a major role in the 
immune system, specifically in regulating cell trafficking and homing of various 
immune cells. The presence of chemokine receptors are needed for a cell to 
respond to chemokines. Chemokine receptors belong to the seven 
transmembrane domain G protein coupled GPCRs family, that when activated 
initiate intracellular signalling, resulting in activation of small GTPases, and then 
downstream activation of integrins (molecules involved in cell adhesion) leading 
to cell movement. There are about 47 known chemokines and 19 chemokine 
receptors (Burger 2010). T and B lymphocytes both express receptors for various 
chemokines that are continuously expressed in the tissue microenvironment with 
their expression and function modulated during differentiation and lymphocyte 
activation. Chemokines and their receptors are important factors for organizing 
CLL cell trafficking and homing as well as their cellular interactions between CLL 
and accessory cells. Critical chemokines for CLL include CXCL12, CXCL13, 
CCL19/21 and their receptors CXCR4, CXCR5 and CCR7 respectively. 
Chemokines secreted by CLL cells are important in the recruitment of accessory 
cells. Other proteins that play a vital role in directing CLL cell migration within the 
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tissue microenvironment are integrins such as VLA-4 (CD49d) as well as 
selectins, MMP-9 and CD44 (Davids & Burger, 2013). 
The CXCR4 chemokine receptor was one of the first to be discovered in CLL and 
has a high level of expression on the surface of peripheral blood CLL cells 
compared to B cells from healthy donors (Burger et al. 1999) (Richardson et al., 
2006). CXCR4 expression is downregulated by its ligand CXCL12 (previously 
known as stromal cell derived factor-1 / SDF-1) via receptor endocytosis. 
CXCL12 is produced within primary and secondary lymphoid tissues, in non 
lymphoid tissues (homeostatic), and areas of increased encounter with antigens. 
Furthermore, CXCL12 induces phosphorylation of molecules involved in the 
formation of focal adhesions and reorganization of the cytoskeleton (Ticchioni et 
al., 2002). This chemokine has two major effects on CLL cells mediated through 
the CXCR4 receptor: (1) migration towards stromal cells and (2) provision of 
survival signals. CXCL12 not only affects CLL cell migration, but also provides a 
pro survival effect on CLL cells (Burger 2010). Quiroga et al. (2009) had shown 
that BCR signalling results in down regulation of CXCR4, along with enhanced 




             
Figure 9: CLL cell migration (Devereux & Cuthill, 2017). Migration of CLL 
cells to proliferation centres is mediated by chemokine ligand 19 (CLL19) and 
21(CCL21) via CC-chemokine receptor 7 (CCR7). These chemokines are 
produced by endothelial cells. In addition, migration can be mediated through 
CXCR4 in response to CXC-chemokine ligand 12 (CXCL12).  
 
 
In addition to CXCR4, another receptor in CLL is the CCR7 receptor for 
chemokines CCL19 and CCL21, which are constitutively expressed by 
fibroblastic reticular cells, high endothelial venules (HEVs) and dendritic cells 
(DCS). In addition, CCR7 is expressed by CLL cells and migrates across 
vascular endothelium in response to CCL19 and CCL21 (Till et al. 2002). These 
chemokines are important in lymph node homing of naïve and regulatory T cells 
and DCS (Burger 2010). Finally, there is a correlation between migration index of 
B-CLL in response to CCR7 ligand and presence of clinical lymphadenopathy 
(López.Giral et al., 2004) (Figure 9). 
Two other chemokines that have been found to be highly expressed and 
secreted by activated CLL cells are CCL3 and CCL4. These chemokines are 
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elevated in the plasma of CLL cells and are associated with poor prognosis. Data 
suggests that these chemokines function by recruiting CCR5+ regulatory T cells 
close to B cells, to provide highly efficient survival signals to B cells (Davids & 
Burger, 2013). CLL cells upregulate and secrete CCL3/4 in response to BCR 
stimulation in co culture with nurse like cells (NLCs) imitating the lymphatic tissue 
microenvironment.   
 
2.9.2 Role of ZAP70 in Migration 
ZAP70 expression is associated with higher responsiveness to BCR stimulation. 
ZAP70 positive CLL cells display increased chemotaxis and survival in response 
to CXCL12, CCL19 and CCL21 compared to ZAP70 negative CLL cells similar to 
CD38+ve CLL cells (Burger 2010). As previously mentioned, CXCR4 is more 
greatly expressed in B CLL cells compared to healthy donors, however 
comparing ZAP70 positive and ZAP70 negative patients, there is no significant 
difference in expression (Richardson et al., 2006). Ticchioni et al, 2002 showed 
that ZAP70 is required for CXCR4 signal transduction. Inhibition or absence of 
ZAP70 (Jurkat T cells/ primary CD4+ T cells ZAP70 negative patients) showed a 
lack of transendothelial migration rescued by transfection of ZAP70. Also, 
CXCL12 resulted in increased intracellular levels of F actin but no significant 
difference between ZAP70 positive and ZAP70 negative patients. However, CLL 
cell migration was significantly greater in ZAP70 positive CLL cells compared to 
ZAP70 negative cells towards CCL19 and CCL21 but not CXCL12 (Richardson 
et al., 2006).   
Furthermore, CXCL12 induced phosphorylation of ZAP70, VAV1 and ERK, 
suggesting cross talk between ZAP70 and CXCR4. This crosstalk is needed for T 
cell migration (Ticchioni et al., 2002). Similarly, CXC12 treatment induced quick 
phosphorylation of ERK1 and ERK2 as early as two minutes with sustained 
signalling for up to 2 hours in ZAP70 positive cells (Richardson et al., 2006). 
Using an ectopic expressing Ramos cell line, it was shown that there was 
increased expression of CCR7 via ERK1/2 post IgM signalling which resulted in 





2.10         Aims of this Study 
 
CLL is a malignancy of CD5+ B cells (Devereux & Cuthill, 2017). The differences 
between the two subtypes (M-CLL and UM-CLL) and their effects on disease 
prognosis has been well reported. In CLL, ZAP70 is a prognostic marker, 
however, the role of ZAP70 in B CLL remains elusive.  
My goal in this study is to characterise involvement of ZAP70 in the pathogenesis 
of CLL. Based on published data (Chen et al., 2008; Gobessi et al., 2007; J. et 
al., 2010; Laufer, Lyck, & Legler, 2018), I set out to test my hypothesis that 
ZAP70 enhances BCR signalling with ramifications for cell proliferation, survival 
and migration. Specifically, reduction of ZAP70 kinase activity would decrease 
calcium mobilization, survival and proliferation of B CLL. Further downstream to 
BCR signalling, I hypothesise that reduced levels of ZAP70 would reduce 
phosphorylation levels of AKT and p65.  In addition to the effect on BCR 
signalling, a further hypothesis is that ZAP70 in B CLL increases CLL cell 
migration. Lastly, based on data from the Ringshausen lab, where it was found 
that CLL cells had nuclear expression of ZAP70, and ZAP70 positive patients 
had poor prognosis. I hypothesise that nuclear ZAP70 contributes to DNA 
instability following genotoxic insults. All of my hypotheses will be investigated 
using the selective dual SYK/ZAP70 inhibitor P505-15 as well as using siRNA to 
knockdown ZAP70 in primary CLL cells. Finally, different mass spectrometry 
approaches will be explored to understand interacting partners of ZAP70 in BJAB 
and B CLL cells at both the steady state as well as upon anti IgM activation. This 






3. Materials and Methods 
 
3.1         Materials 
3.1.1 Overview of siRNA primers  
ZAP70 siRNA (siZAP70): Life Technologies: HSS187732, HSS187733, 
HSS187734. 
Non-specific siRNA (siNSC): Thermofisher Scientific 12935300 
SYK siRNA (siSYK): Life Technologies: SYKHSS110401, SYKHSS110402, 
SYKHSS186171  
3.1.2 Retroviral vectors  
pRetroCMV /T0/ Puro/GFP 
pRetroCMV /T0/ Puro/ 
3.1.3 Overview of western blot antibodies used in this study 
Table 1 – List of Antibodies used for western blotting 
Antigen Catalogue  
Number 
Company 
MOUSE ANTI ZAP-70 
KINASE  
610240 BD Bioscience 
ZAP70 (L1E5) Mouse 
mAb 
2709 Cell Signalling  
pZAP70 Tyr 319/pSYK 
Tyr 352 (65E4) Rabbit 
mAb  
2717      Cell Signalling 
ZAP70 (LR) SC-574 Santa Cruz 
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pBTK 87141 Cell Signalling 
p-pERK 9101    Cell Signalling 
β actin  13 E5 Rabbit 
mAb (HRP conjugate)  
5125 Cell Signalling 
RPl29  GTX101833 GeneTex 
RPL37  GTX104688      GeneTex 
Anti V5   R960-25 Invitrogen 
FLAG F3165    Sigma 
APC Mouse Anti 
human CD19 
555415 BD Pharmingen 
Alexa Fluor 647 Mouse 
anti H2AX(pS139)      
560447      BD Pharmingen 
SYK (D115Q) Rabbit 
mAb 
12358 Cell Signalling 
Phospho-NF-κB      p65 
(Ser536) (93H1) Rabbit 
mAb 
3033      Cell Signalling  
NF-κB p65 (L8F6) 
Mouse mAb 
6956 Cell Signalling  
 




R-PE CLONE IE7.2 
MHZAP7004  Invitrogen      
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Phospho Btk (Tyr223)  5082 Cell Signalling  
Anti BTK Ab137503 Abcam  
Anti Mouse IgG 
RMG07 
Ab197767 Abcam 
Anti Rabbit  IgG(H+L) 
F(ab’)2 488 conjugate 
4412      Cell Signalling  
Phospho-Histone H2A-
X(Ser139) 
2577 Cell Signalling     
Histone H2A  2578 Cell Signalling 
Alexa 647 Mouse IgG1 
K isotype control 
557783 BD Bioscience  
Rabbit IgG Polyclonal 
Isotype control 
Ab27478 Abcam 
Phospho-AKT(Ser 473) 4060 Cell Signalling 











3.1.4 Overview of cell lines 
Table 2 - List of B cell lines used in this study. 
Cell line  Type Source 
Mec 1  CLL       Dr Ringshausen 
BJAB DLBCL      Dr Hodson 
HBL1 DLBCL      Dr Hodson      
RAJI DLBCL      Dr Hodson      
 
3.1.5 Overview of qRT-PCR primers used in this study  
Table 3 - List of qRT-PCR primers 
Primer Sequence 
ZAP70 Forward  TATGGGAAGACGGTGTACCA 
ZAP70 Reverse  AGAGCGTGTCAAACTTGGTG 
GAPDH Forward GTGAAGGTCGGAGTCAACG 









3.1.6 Cloning Primers  




T      




BAMHI ZAP70 R CCACCACACTGGACTAGTGGATC
CTCAGGCACAGGCAGCCTCAG 
 
3.1.7 ZAP70 Sequencing primers 

















3.1.8 Overview of Chemokines  
Table 6: List of chemokines used in this study. 
Chemokine  Company  Catalogue number 
CCL21 Recombinant 
Human Exodus-2     
Peprotech      300-35 
CCL19  Recombinant 
Human MIP-3B     
Peprotech            300-29B 
CXCL12  Recombinant 
Human SDF-1A    










3.1.9 Overview of inhibitors 
Table 7: List of Inhibitors used in this study. 
Company Catalogue Number Inhibitor 
Selleckchem S8032 PRT062607 (P505-15, 
BIIB057) HCL 




Selleckchem S1212 Bendamustine HCL  
 
3.1.10   Media and Buffers 
CLL media: 500ml RPMI1640 + 5% Foetal Bovine Serum (FBS) + 50IU/ml 
Penicillin/streptomycin (Gibco) + 2mM L–Glutamine (Gibco) + 10mM HEPES 
(Gibco) + 0.7X Non-Essential Amino acids (Gibco) + 1mM Sodium Pyruvate 
(Gibco) + 0.05mM 2.mercaptoethanol 
 
Cell lines: RPMI 1640 +10% FBS + penicillin/streptomycin/Glutamax 
DMEM +10% FBS + penicillin/streptomycin 
 
Staining buffer: 500ml of PBS + 1% FBS + 0.01% Sodium Azide 




Nuclear extraction buffer A: 10mM HEPES pH7.9 +10mM KCL+300mM 
Sucrose+1.5mM MgCl2+ 0.5mM DTT+ 0.1% NP.40+ 0.5mM PMSF +1x 
cOmplete mini protease inhibitor 
 
Nuclear extraction buffer B: 20mM HEPES pH7.9+ 100mM KCL+ 100mM 
NaCl+ 0.5mM DTT+ 20% glycerol + 0.5mM PMSF+ 1X cOmplete mini protease 
inhibitor (Roche)  
 
Western Blot Buffers:  
10X Running Buffer 
       Tris base (30.2g) + SDS (10g)+Glycine (144g) +water (up to 1000ml)  
10X Transfer buffer  
      Tris base (30.2g)+ Glycine (144g) + water (up to 1000ml)  
1X Transfer buffer  
     10X transfer buffer (100ml) + Methanol (200ml) + water (700ml)  
10X TBS 
     Tris HCL (70.04g) + Tris base (6.66g) + NaCl (87.6g)  
1X TBST  
      10X TBS (100ml) + Tween (1ml) + water (up to 1000ml)  
Blocking buffer  









Western blot polyacrylamide gel recipes: 
Table 8 - Recipes for Running Gels (2 x (4ml) gels)  
Reagent 
Percentage Gel 
8% 10% 12% 
ddH2O 3.7ml 3.2ml 2.6ml 
30% Acrylamide 2.13ml 2.67ml 3.2ml 
1.5M Tris pH 8.8 2ml 2ml 2ml 
10% SDS 80µL 80µL 80µL 
10% APS 80µL 80µL 80µL 
TEMED 8µL 8µL 8µL 
 





30% Acrylamide 0.8ml 
0.5M Tris pH 6.8 1ml 
10% SDS 40µL 








3.2          Methods 
3.2.1  Cell culture 
BJAB BirA, HBL.1 BirA and Raji BirA cell lines were obtained from Dr Daniel 
Hodson and cultured in RPMI 1640 (Gibco) + 10% FBS + penicillin streptomycin 
and Glutamax (Gibco).  
HEK 293 cells were cultured with DMEM (Sigma) + 10% FBS and penicillin/ 
streptomycin (Gibco) 
For the inducible system, 100ng/ml of Doxycycline Hydrochloride (Sigma D3072) 
was used. 
3.2.2  Isolation of PBMC from CLL patient blood samples.  
Peripheral blood was collected from consented patients followed by PBMCs 
isolation using Ficoll-Paque plus as follows:  blood was firstly diluted 1:1 in PBS 
and then carefully layered over 15ml of Ficoll dropwise. The blood Ficoll mixture 
was then centrifuged for 15 minutes at 880rcf at room temperature with no 
brakes. The cloudy interphase was then transferred into a new 50ml falcon tube 
and centrifuged for 10 minutes at 450rcf with brakes. The pellet was then 
resuspended in 10ml of CLL media and centrifuged again for 5 minutes at 880rcf. 
The pellet was then resuspended in 10ml of Pharmlyse (BD Biosciences) and 
incubated at room temperature for 10 minutes. After centrifugation, the cells were 
resuspended in 10ml of CLL media and cell purity experiments were carried out 
as described in section 3.2.5 and ZAP70 status determined as described in 3.2.6. 
Vials of white blood cells (WBC) were frozen down for all future experiments.  
3.2.3      Flow cytometry  
Antibodies and isotype controls used for flow cytometry measurements were 
purchased from Biolegend, ebioscience or BD Biosciences. All flow cytometry 





3.2.4      CLL Cell purity    
Following isolation of PBMC, 1X106 cells were washed once with staining buffer 
and centrifuged for 5 minutes at 500rcf. Cells were then suspended in 100µl of 
staining buffer. For CLL cell staining, 2µl of CD5 and 2ul of CD19 antibody were 
added to the tube and incubated for 20 minutes in the dark at room temperature. 
The cells were then washed once with 500µl of staining buffer and analysed 
using flow cytometry. Samples greater that 85% CLL purity (CD5+19+) were 
used for the experiments.  
3.2.5  ZAP70 expression in CLL cells 
For the ZAP70 staining, appropriate samples were stained with CD19 only for 20 
minutes at room temperature in the dark and then fixed with 300µl of fixation 
buffer and incubated for 15 minutes at room temperature in the dark followed by 
2 washes with 1x permeabilisation/wash buffer. The cells were then suspended 
in 100µl of 1x permeabilisation/wash buffer and 5µl of R.PE. conjugated 
monoclonal antibody against ZAP70 (clone 1E7.2), appropriate isotype controls 
were added to the cells in appropriate tubes, before incubating for 20 minutes at 
room temperature in the dark. Finally the cells were washed with staining buffer, 
resuspended in 300µl of staining buffer and analysed by flow cytometry using BD 
LSR II (BD Biosciences, San Jose, CA). Figure 10 shows the flow cytometry plot 
of a ZAP70 positive (31.4%) and ZAP70 negative (12.8%) patient sample. The 




















Figure 10: CD19/ZAP70 staining on CLL patient samples. Left panel shows a 
negative patient (CD19+ZAP70+= 12.8%) below 20% cut off . Right panel shows 
a positive patient (CD19+ZAP70+= 31.4%) above 20% cut off. 
3.2.6    Cloning of pRCMV_FL_BIO_ZAP70 wild-type/mutant (+/- GFP). 
ZAP70 was PCR amplified from a pcDNA4 ZAP70 WT or Mutant vector 
(Ringshausen group) respectively and inserted into the pRetroCMV /T0/ 
Puro/GFP and pRetroCMV /T0/ Puro vector (Dr. Daniel Hodson) by Gibson 
assembly (Figure 11). 
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Figure 11: Schematic of cloning to generate cell lines utilized for in vivo 
biotinylation. ZAP70 was amplified from pCDNA4 and inserted int pRetroCMV 
using Gibson assembly following by transduction into cell lines expressing BirA.  
   
ZAP70WT/ 
ZAP70 Mutant  
Gibson 
assembly 











3.2.7    Transfections and Retroviral Transductions 
Single suspensions of HEK293T cells were plated on a 6 well dish to achieve 
about 40% confluency in preparation transfection. Transfection was performed 
24 hours after seeding using room temperature TransIT-293 (Mirus) (vortexed 
well). In 200µl of 1x PBS (no FBS), 3.6µl of TransIT-293 was added, mixed well 
and incubated for 10 minutes at room temperature. After incubation, 200ng of 
packaging plasmid (DH28 and DH29) and 800ng of retroviral plasmid were 
vortexed and added. This mixture was further incubated for 45 minutes at room 
temperature and then added drop wise onto the cells, which was swirled around 
gently to mix with the cell media. The cells were then incubated overnight at 
37oC. Retroviral supernatant was harvested 48 hours post transfection and spun 
down at 2500rpm for 10minutes at 4oC. The supernatant had 25mM HEPES and 
10µg/ml Polybrene added, which was then dispensed over the cells in a 24 well 
plate, plated with BJAB/HBL1/Raji cells at 40% confluency, and mixed gently. 
The cells and supernatant were then spun at 2500g for 1 hour and 30 minutes at 
30oC. After centrifugation, most of the media was aspirated and replaced with 
cell line appropriate media. After protein expression was seen (48-72 hours), 
antibiotic selection was carried out by adding 2µg/ml of puromycin and allowed to 
grow for a few more days. 
3.2.8    In vivo biotinylation 
Cell lines (BJAB, HBL1 and RAJI) containing the BirA were obtained from Dr 
Daniel Hodson’s lab. BirA is the Escherichia coli biotin ligase. This approach is 
based on the fusion of an Escherichia coli biotin protein ligase fused to a 
targeting protein.  It recognizes and biotinylates a lysine side chain within a 15 
amino acid acceptor peptide (bio sequence). These lines have the advantage of 






3.2.9    Streptavidin pull down  
10% of total lysate was saved as “input”. Remaining lysate was incubated for 4 
hours with 10µl of MyOne streptavidin T1 (Dynabeads 65601) at 40C with rotation 
brought up to 500µl using lysis buffer, the flow through was saved and the beads 
were washed five times with PBS prior to elution. Western blot analysis was 
performed using 5% of each fraction. 
3.2.10     Pull down of endogenous ZAP70 from primary cells (IgM 
activation) 
Rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) 
protocol (Mohammed et al., 2016) was followed with a few modifications as 
described below.  
Each condition utilised 20x106 purified CLL cells. Post activation of cells were 
fixed DSG (disuccinimidyl glutarate) for 20 minutes at room temperature. 1% 
formaldehyde in serum free media was added to the DSG +cells for 10 minutes 
at room temperature. Equal volume of 1.25M Glycine was added to stop fixation. 
Cells were washed twice with ice cold PBS. Cells were then re-suspended in 1ml 
of Pierce IP lysis buffer (87787) and freeze/thawed three times on dry ice. Lysed 
cells were spun at 14,000rcf for 10 minutes. Supernatant (cytoplasmic fraction) 
was added to prewashed Protein G Dynabeads (Life Technologies 10003D) or 
Protein A Dynabeads (Life Technologies 10001D) and rotated for 4 hours at 4oC. 
The supernatant was added to a magnetic rack whereby the beads bound to the 
magnet. Some of the supernatant was saved as input for western blots, the 
remaining supernatant was divided into two tubes containing:  ZAP70 Antibody 
(20µg) and anti IgG (20µg) respectively and incubated overnight at 4oC with 
rotation. The following day, prewashed beads were added and further incubated 
for 4 hours at 4oC with rotation. After incubation, the beads were bound to a 
magnetic rack and the supernatant was saved as flow through. Beads were 
washed 5X with 1X cold PBS. On the last wash 10µl of beads were saved for 
western blots. Remaining beads were washed with cold ammonium hydrogen 
carbonate (AMBIC) solution twice. The beads were dried and submitted for mass 




3.2.11     Western blotting 
Cells were collected in a conical tube and centrifuged for 5 minutes at 500rcf. 
The pellet was then resuspended in 10ml of PBS and centrifuged for 5 minutes at 
500rcf. The pellet was resuspended in 1ml of PBS and transferred to a 1.5ml 
microcentrifuge tube before pelleting at 12,000rcf for 5 minutes. Supernatant was 
discarded and cell pellets were lysed using RIPA buffer (1M tris pH 7.4, 5M NaCl, 
Sodium Deoxycholate, IGEPAL, SDS and water) supplemented with HALT 
phosphatase inhibitor cocktail (Thermo Scientific: 78420) and HALT protease 
inhibitor cocktail (Thermo Scientific: 87786) which was incubated for 30 minutes 
on ice or RIPA 10X buffer (Cell Signalling: 9806). The tubes were then spun 
down at 16,000rcf for 5 minutes at 4oC. Supernatant (protein lysate) was 
collected and quantified using the BCA assay. Equal amounts of samples were 
then loaded onto a 10% sodium dodecyl sulfate polyacrylamide gel (SDS PAGE) 
and further transferred on PVDF membranes. Primary antibodies were used with 
the HRP immunodetection system to detect human proteins. Western blot 
antibodies were purchased from either BD Biosciences, Santa Cruz 
Biotechnology, Cell Signalling or Abcam (Table 1).  
3.2.12 Calcium flux assay 
Media without any supplements was warmed in water at 37oC. 5x106 cells were 
spun down at 500rcf for 5 minutes. The cell pellet was resuspended in 500µl of 
serum free media before adding 2µl of Fluo-4 (Invitrogen) to each sample and 
incubating for 15 minutes at room temperature in the dark. Fluo-4 is a fluorescent 
dye developed for quantification of cellular Ca2+ concentration. Cells were then 
washed once with HBSS (Ca++ free) + 1% FBS. Cells were resuspended in 
100µl of HBSS and incubated for 20 minutes on ice in the dark with 20µg of 
biotinylated IgM. Cells were then washed with HBSS and resuspended in 500µl 
of HBSS and incubated for 20 minutes at 37oC. Before measurements were 
taken on the flow cytometer, DAPI was added to each sample and 
measurements were taken by recording background signalling, pausing after 30 
seconds by removing the tube and quickly adding 20µg of streptavidin (N7021S) 
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and resuming measurements for 3 minutes. Change in calcium influx was 
calculated by subtracting fluorescence intensity peak value before stimulation 
from fluorescence intensity peak value after stimulation.  
3.2.13 BCR Stimulation 
BCR stimulation was performed by adding Biotin SP conjugated affinipure Fab 
fragment goat anti IgM Fc5µ fragment specific (Jackson Immunoresearch 
Laboratories: 109-067-043) at a final concentration of 20µg/ml for 20 minutes on 
ice. Cells were washed with ice cold PBS and incubated for 20 minutes at 37oC. 
20µg of streptavidin was then added at varying timepoints according to 
experimental requirements.  
BCR activation was also carried out with immobilized IgM with Dynabeads M280 
Streptavidin, (Invitrogen 11205D). For this IgM and prewashed streptavidin 
beads were rotated for 1 hour at room temperature, this mixture was then added 
to cells according to the BCR stimulation protocol above.  
3.2.14 Subcellular fractionization 
Cell pellets were washed with ice cold PBS and lysed with nuclear extraction 
buffer A for 5 minutes on ice. The nuclear pellets were centrifuged for 5 seconds 
at 13,200rpm. The supernatant was saved as cytosolic fraction. The pellet was 
then further lysed with nuclear extraction buffer B and sonicated for 30 seconds. 
The lysate was then centrifuged for 5 seconds at 13,200rpm to pellet the debris, 
and the supernatant (nuclear fraction) was saved. Protein lysate was run on SDS 
PAGE gel.   
3.2.15 Quantitative expression of ZAP70 by real time PCR (qPCR)  
Cultured cells were spun down at 500rcf for 5 minutes. Cell pellet was washed 
once with PBS and RNA extraction using the QIAGEN RNA isolation kit following 
the manufacturers protocol. The RNA was quantified using the Nanodrop and 
500-1,000ng of RNA was used to make cDNA using the high capacity cDNA 
reverse transcriptase kit (Life Technologies). The cDNA was then used alongside 
primers specific to genes of interest and the SYBR green qPCR mix (Life 
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Technologies) for real time PCR assay. Normalization was carried out using 
GAPDH and fold changes were calculated using ΔΔct method.  
3.2.16 Knockdown of ZAP70 using siRNA  
Patient samples were thawed, counted and 10x106 cells were used for 
nucleofection. The CLL cells were resuspended in 100µl of Nucleofection 
solution (Lonza) and 0.67µg of each ZAP70 siRNA (set of 3) or 2µg of NSC 
siRNA and transferred to cuvette for nucleofection using Amaxa nucleofector 
programme X-001. Post nucleofection, cells were transferred to eppendorf tubes 
and spun at 500rcf for 5mins. The cell pellet was resuspended using CLL media 
and plated on stromal cells (plated the day before) in CLL media. Cells were 
incubated for 1 week at 37oC 5% CO2.  
3.2.17 DNA Damage (irradiation/chemotherapy and treatment) 
Patient samples were thawed, counted and plated on stromal cells to recover for 
24 hours. Cells were pre treated with KU55933 (Selleckchem), ZAP70 inhibitor or 
siRNA knockdown nucleofection was carried out prior to DNA damage. 
Irradiation dose rate used was 4Gy. Cells were transferred to a 37oC 5%CO2 
incubator and cells were harvested for western blot analysis 1 hour post 
radiation. Bendamustine (Selleckchem) was used at a concentration of 30µM for 
24 hours to induce DNA damage.  
Apoptosis detection: Annexin V FACS staining was carried out 48 hours post 
radiation or chemotherapy drug treatment.  
3.2.18 Comet assay  
Cells were prepared and treated with inhibitor prior to radiation to induce double 
stranded breaks (DSB), carried out as described previously. The comet agarose 
bottle was heated at 95oC in a water bath for 20 minutes to liquefy. The agarose 
bottle was then transferred to 37oC until required. Reagents were prepared 
according to the manufacturers protocol (OxiSelect Comet assay Kit: STA-350). 
Briefly, cells were prepared and combined with comet agarose at 1:10 ratio by 
pipetting and 75µl/well was immediately transferred onto the top of the comet 
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agarose base layer. The slide was then transferred horizontally to 4oC in the dark 
for 15 minutes. The slide was then transferred to a small basin containing pre 
chilled lysis buffer carefully before immersing in the buffer for 60 minutes at 4oC 
in the dark. The lysis buffer was then gently aspirated and replaced with pre 
chilled alkaline solution for another 30 minutes at 4oC in the dark. The alkaline 
buffer was then aspirated and replaced with pre chilled TBE electrophoresis 
solution for 5 minutes and repeated once more. The slide was gently placed in 
the electrophoresis chamber and a voltage of 1volt/cm was applied for 10-15 
minutes. The slide was moved to a container containing pre chilled DI H2O. The 
slide was then placed in cold 70% Ethanol for 5 minutes and allowed to dry. 
100µl/well of diluted vista green DNA dye was added to the slide and incubated 
at room temperature for 15 minutes. The slides were viewed under a fluorescent 
microscope using a FITC filter.  
3.2.19 Migration assay  
CLL cells post treatment were resuspended in RPMI1640 with 5% FBS. From 
this 5x105 cells were added to the top chamber of a 6.5mm diameter transwell 
culture insert with a pore size of 5µM. Filters with cells were transferred into wells 
containing medium with the chemokines CXCL12 (100ng/ml), CCL19 (1µg/ml), 
and CCL21 (1µg/ml) or media alone. The chambers were incubated for 3 hours 
at 37oC in 5% CO2. Post incubation cells in the lower chamber were thoroughly 
resuspended, stained with CD5/CD19 and counted using CountBright Absolute 
counting beads according to the manufacturers protocol. The migration index 
was calculated as the number of cells transmigrating with chemokine divided by 
the number of transmigrating cells in the absence of chemokine.  
3.2.20 Proliferation assay  
CLL cells were co-cultured with EL08 cells expressing CD40/IL21. EL08 is a 
murine cell line characterised as a stromal cell line to aid in maintaining CLL cells 
in vitro. After inhibitor treatment, 2x106 CLL cells were harvested and washed 
once with PBS. The cell pellet was then incubated with 2.5µM CFSE dye, 
resuspended in PBS (37oC), and incubated for 20 minutes at 37oC in an 
incubator whilst being protected from light. Culture media was added to the cells 
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and incubated for 5 minutes to remove any free dye. Cells were then centrifuged 
and resuspended in fresh media and incubated for 6 days at 37oC prior to FACS 
staining and analysis. 
3.2.21 Apoptosis assay 
      The apoptosis assay was carried out using the Annexin V kit (Biolegend) and 
DAPI (4’6-diamidino-2-phenylindole) according to manufacturers instructions. 
Double negative (DAPI negative and Annexin V negative) cells were referred to 
as live cells in this thesis.  
3.2.22 OPP Protein Synthesis assay   
Click-iT OPP (O-propargyl-puromycin) kits (Thermofisher) was used to detect 
newly synthesized proteins. Experiments were conducted according to the 
manufacturer’s protocol.  
3.2.23     Statistical analysis  
Significant differences between groups were assessed using paired T test using 
Graphpad Prism 6 software. Significance were denoted as follows:  ns (P>0.05), 
* (P≤0.05), **(P≤0.01) and ***(P≤0.001). Error bars used throughout this thesis is 














4.1             Function of ZAP70 in CLL cells 
 
BCR signalling plays an important role in chronic lymphocytic leukaemia. In vivo, 
mutated CLL (good prognosis) is driven towards anergy whereas unmutated CLL 
show less anergy. Continuous anergy has a decreasing effect on adhesion and 
migration, thereby having an overall effect on cell signalling, cell survival and 
proliferation (Packham et al., 2014). It has been suggested that ZAP70 enhances 
BCR signalling which causes increased CLL cell survival via Bim regulation, and 
proliferation (Paterson et al., 2012) . 
4.1.1   P505-15 decreases calcium mobilization in CLL cells   
UM-CLL cells are more responsive to surface IgM activation (increased calcium 
mobilization) resulting in tumour progression. CLL cells transduced with ZAP70 
wildtype, a kinase defective ZAP70 ( ZAPP-70 KA 369) or ZAP70 unable to bind 
to c-CBL have shown increased intracellular calcium flux compared to mock 
transduced CLL cells lacking ZAP-70 (Chen et al., 2008).  It has been shown that 
cells from ZAP70 positive patients have greater calcium flux compared to ZAP70 
negative CLL patient cells (Chen et al., 2005b) and activation of PLCϒ induces 
mobilization of intracellular calcium that can be measured via flow cytometry. 
Here, P505-15 was used to inhibit ZAP70 kinase activity and ibrutinib to inhibit 
BTK activity (positive control).  ZAP70 positive patient CLL cells were cultured in 
CLL media and treated with two concentrations of P505-15, 5µM and 0.25µM. 
Post treatment, calcium mobilization was measured using the calcium flux assay 
(Figure 12). After acquiring calcium flux measurements post addition of IgM, 
Ionomycin was subsequently added to release all calcium. Calculations on how 
peak fluorescent changes were measured is described in the methods sections 
calcium flux assay 3.2.12. 
Figure 12A shows quantification results of peak fluorescent intensity using 9 
ZAP70 positive CLL cells and representative FACS plots (Figure 12B) of the 
changes seen post treatment. Specifically, significant reduction in peak 
fluorescence intensity was seen comparing untreated to high concentration of 
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P505-15 inhibitor. A similar level of reduction is seen with ibrutinib at both 5µM 
and 0.25µM concentrations. 
 
               
Figure 12: P505-15 treatment reduces BCR signalling in CLL cells. 
Quantification of calcium flux using cells from ZAP70 positive patients, n=9 (A) 
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4.1.2   P505-15 reduces CLL cell viability 
In non transformed cells, anergy increases susceptibility to apoptosis however in 
leukemic cells this is countered by overexpression of the B-cell lymphoma-2 
survival protein (BCL2) (Packham et al., 2014). In normal cells, anti-IgM induced 
phosphorylation of BIMEL, however in CLL cells surface IgM stimulation 
increased phosphorylation of 2 BIM isoforms: BIMEL and BIML resulting in BIM 
degradation. This IgM induced phosphorylation in CLL correlated with unmutated 
IgHV gene status and disease progression (Paterson et al., 2012).  
To investigate whether inhibition of ZAP70 kinase activity affects CLL cell 
survival, Annexin V staining was performed on CLL patient cells treated with 
P505-15 and ibrutinib, in the presence or absence of IgM activation for 24 hours 
(Figure 13A) and 48 hours (Figure 13B). The assay showed significant 
reductions in viability with 5µM but not at 0.5µM of P505-15 at 24 hours 
compared to the vehicle control. However, at 48 hours significant reduction was      
observed at both 5µM and 0.5µM of P505-15. Similar observations were made 
irrespective of IgM addition as well as with ibrutinib treatment used as positive 
control (Figure 13). For both 24 and 48 hour timepoints, all conditions were 




                 
                
Figure 13: P505-15 decreases cell viability. Reduction in cell viability after 
P505-15 and ibrutinib treatment of ZAP70 positive CLL cells at 24 hours (A) and 
48 hours (B) irrespective of IgM activation. Cells treated with P505-15 and 
ibrutinib were harvested at respective timepoints for CLL cell and Annexin V 
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4.1.3   P505-15 significantly reduces CLL cell proliferation 
CLL cells do not proliferate in the peripheral blood, however they are found 
associated with CD40L+/CD4+ T helper (Th) cells and dendritic cells in the 
proliferation centres (PC). Higher proliferative capacity was observed in the UM-
CLL compared to M-CLL correlated with higher phospho-BTK and greater 
sensitivity to Ibrutinib. BTK activity is responsible for increased cell proliferation 
confirmed by siRNA knockdown studies (Guo et al., 2016). 
To investigate whether the inhibition of ZAP70 kinase affects CLL cell 
proliferation, CLL cells were co-cultured with EL08 cells expressing CD40L/IL21. 
Cells were then treated with P505-15 and changes in proliferation were 
assessed. As seen in Figure 14, there is a dose dependent significant decrease 
in percent proliferation (CFSE) upon treatment of CLL patient cells with P505-15. 
Ibrutinib was used as a positive control to reduce proliferation.  
Based on these results, it is clear that P505-15 causes a significant decrease in 
calcium mobilization, viability and proliferation in ZAP70 positive CLL cells.  
Since, P505-15 is not specific for ZAP70, it is vital to specifically unravel the role 
of ZAP70 expression with minimal effect on other tyrosine kinases such as SYK 





             
                            
Figure 14: P505-15 decreases CLL cell proliferation. Reduction in proliferation 
post P505-15 inhibition, quantification of proliferating cells (A) and representative 
FACS plots showing division of cells with CFSE dye (B). Proliferation was 
determined by dilution of CFSE dye as cells divided, showing approximately 3-4 
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4.2           siZAP70 lowers ZAP70 levels with no effect on SYK  
expression.   
   
  Specific knockdown of ZAP70 expression was achieved using siRNA 
nucleofection with minimal effect on other proteins. Notably, due to a long half-life 
of ZAP70, knock down required the prolonged culture of nucleofected cells on 
stroma for a minimum of 6 days. Figure 15A shows ZAP70 siRNA knockdown in 
two ZAP70 positive patient cells with varying amount of endogenous ZAP70 as 
seen in media (un-nucleofected cells). ZAP70 positive cells were nucleofected 
with 2µg siRNA and co-cultured with EL08 cells for 6 days. Comparing siZAP70 
to siNSC, there is a decrease in ZAP70 expression at day 6 post-nucleofection 
with minimal change in SYK expression. Figure 15B shows quantification of 
ZAP70 and SYK expression levels using results from 7 patients. Image J was 
used for quantification of ZAP70 and SYK expression normalized to β actin. 
 
Figure 15: Reduction of ZAP70 expression post ZAP70 siRNA nucleofection 
with minimal effect on SYK expression using ZAP70 positive CLL patient 
cells. (A) representative western blot of ZAP70, SYK and β actin and (B) ImageJ 
quantification of ZAP70 and SYK expression normalized to β actin. 














































































4.2.1   siZAP70 has no effect on calcium mobilization on CLL cells.  
    To test if ZAP70 siRNA knockdown affects calcium mobilization, calcium flux 
assay was carried out on ZAP70 and NSC siRNA treated cells. As seen in Figure 
16, there was no significant difference in calcium mobilization between siZAP70 
and siNSC cells. Non significant reduction in cell viability post knockdown was 
observed as shown in figure 37. 
    
Figure 16: Unchanged BCR signalling post ZAP70 knockdown. 
ZAP70 positive CLL cells were nucleofected with siZAP70 and siNSC and co 
cultured with EL08 for 6 days. On day 6, cells were harvested for calcium flux 
assay. Quantification is based on 8 CLL ZAP70 positive patient cells. 
Quantification achieved by subtracting peak fluorescent intensity in region 1 
(baseline) from peak fluorescence intensity of region 2 (A). Representative FACS 
plots showing calcium flux kinetics (B).  
 























































4.3           Regulation of AKT in CLL cells 
 
AKT is downstream of the signalling cascade following BCR ligation. B cells co 
cultured with marrow stromal cells highlighted the importance of PI3K/AKT 
signalling to support survival of CLL B cells (Ding et al., 2010)      
In unstimulated CLL cells, Akt is fully activated with phosphorylation at both 
serine 473 and threonine 308 and inhibition of AKT results in apoptosis of CLL 
cells associated with rapid loss of MCL1, mediated by GSK3 and increased 
expression of p53. This shows that AKT is important in the survival of 
unstimulated CLL cells (Zhuang et al., 2010). Furthermore, single cell profiling of 
phosphorylated protein levels in CLL showed that (pS473) was more induced in 
IgHV UM- CLL and significantly higher than in M-CLL (Myhrvold et al., 2018).  As 
mentioned briefly in the introduction, BCR signalling is propagated via PI3K. 
Here, PI3K phosphorylates PIP2 to create PIP3, which recruits BTK and AKT 
and activates the signalling effector mTOR (Bellacosa et al., 1998). It has been 
shown that the mTOR signalling cascade is differentially regulated in distinct 
prognostic CLL cohorts. In addition dual mTORC1/2 inhibitors preferentially 
induce apoptosis of poor prognostic CLL subsets (Cosimo et al., 2019) 
 
4.3.1   siRNA knockdown of ZAP70 increased pAKT in CLL cells. 
Firstly, I wanted to identify the most suitable method and timepoint for BCR 
activation using IgM (soluble/ immobolised) to result in phosphorylation of AKT, 
ERK and BTK. Immobolised IgM resulted in higher and sustained activation 
compared to soluble IgM (not shown). Figure 17A shows pAKT, pERK and pBTK 
levels in the cells activated with immobolised IgM and harvested at 15 minutes, 
60 minutes and 180 minutes (Figure 17A). Maximum phosphorylation of AKT and 
ERK was seen at 1 hour and phosphorylation of BTK observed at 15 minutes.  
To specifically understand the role of ZAP70, I investigated if depletion of ZAP70 
by knockdown would affect AKT phosphorylation. Here, I nucleofected ZAP70 
positive CLL cells with ZAP70 and non-specific siRNA for 6 days co-cultured with 
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EL08 cells. On day 6, cells were activated with immobilised IgM for 1 hour and 
then harvested for western blot assay. ZAP70 siRNA treated cells show increased 
pAKT compared to non specific siRNA treated cells (Figure 17B) and Figure 17C 
shows pAKT levels normalized to total AKT relative to siNSC.   
             
Figure 17: ZAP70 knockdown results in increased AKT phosphorylation. 
Representative western blot showing pAKT 473, pBTK, and pERK at various 
timepoints post immobilised IgM activation (A), Changes in phosphorylation of 
AKT, and ERK on ZAP70 and NSC knockdown cells post IgM activation (B) and 
ImageJ quantification using ZAP70 and NSC siRNA treated cells (n=6) (C). 
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4.3.2   NF-κB activity is unchanged following ZAP70 knockdown 
    CLL cells have been reported to exhibit high constitutive NF-kB activation 
compared to normal B cells due to AKT activation, BCR signalling, and CD40 
ligation (Hewamana et al., 2008). NF-κB is regulated via 2 pathways, in the 
canonical pathway, the inhibitor IκBα binds cytosolic p50 and p65. Once 
activated, IKKβ phosphorylates IκBα thereby promoting its degradation and 
release of p50 and p65, which translocates to the nucleus and activates 
transcription. These transcription factors are key regulators of differentiation and 
survival in B cells. These factors include: c-Rel, RelB, p50, p52, and p65 (RELA) 
(Shih, Tsui, Caldwell, & Hoffmann, 2011) Interestingly, gene expression profiling 
of CLL cells in the LN showed upregulation of BCR gene signature, indicating B 
cell receptor and NF-κB activation is consistent with phosphorylation of SYK and 
IkBα respectively. The expression of BCR target genes was stronger in UM-CLL 
than in M-CLL (Herishanu et al., 2011). Specifically, introduction of functional 
ZAP70 protein in CLL cells with minimal endogenous ZAP70 expression, resulted 
in an increase in IL1B, IL6 and IL8 upon BCR stimulation through an IKK 
dependent mechanism (Pede et al., 2013). In addition, comparing CLL samples 
to normal donors, overexpression of AKT/mTOR related signalling proteins 
resulted in higher phosphoprotein levels of PDK1, 4EBP1, p70S6K, BAD and 
PRAS40 (Shull et al., 2015). Also, CLL cells co-cultured with EL08-1D2 indicate 
that BAD, PRAS40 and glycogen synthase kinase 3-β (GSK3-β) are 
phosphorylated, suggesting a pro-survival signal via PI3K and AKT in CLL cells 
(Mangolini et al., 2018).      
    Here, I am investigating if ZAP70 plays a role in NF-κB activation by knocking 
down ZAP70 expression in ZAP70 positive CLL cells. Firstly, I assessed changes 
in phospho p65 post IgM activation. Figure 18A shows a lack of change in 
phospho p65 in 3 CLL patients post IgM activation following ZAP70 positive cells 
being nucleofected with 2ug of siRNA and cocultured with EL08 for 6 days. On 
day 6, cells were activated with immobolised IgM for a further 24 hours and on 
day 7, cells were harvested for western blot. Figure 18B shows no changes in 
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phospho-p65 comparing ZAP70 and non-specific siRNA. These western blots 
are representative of 6 patient samples.      
    Figure 18C and 18D shows the minimal changes in phospho PRAS40 in the 
ZAP70 siRNA knockdown cells compared to NSC knockdown. Quantification of 
PRAS40 normalised to total PRAS40 was done using ImageJ from 6 patients. 
Comparing ZAP70 and NSC knockdown, despite being non significant 






Figure 18: NF-κB activity post ZAP70 knockdown. (A) Representative western 
blot image of phospho p65 after immobilised IgM activation. (B) Representative 
Western blot of 2 CLL patients that were treated with ZAP70 and NSC siRNA 
followed by 24 hours of immobilised IgM activation at day 6 post nucleofection. 
(C) Changes in phosphor PRAS 40 in the ZAP70 and NSC nucleofected cells (D) 
Quantification of phospho PRAS40 in the ZAP70 and NSC knockdown cells post      
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5. Results: Mass spectrometry unveils ZAP70 protein 
interactors 
 
5.1           RIME/BirA mass spectrometry approach using BJAB cells. 
 
Unravelling protein-protein interactions is a major barrier to understanding 
complex biological processes. Functions of these proteins can only be fully 
understood in the context of networks of interaction. Many techniques like affinity 
capture complex purification and yeast two hybrid strategies have been used in 
the past, but these have limitations such as loss of insoluble or weak/transient 
proteins that are part of the protein interactome and difficulties in extraction, 
digestion and separations, whereby proteins are underrepresented in mass 
spectrometry analysis.  
To enhance identification of these interacting proteins the BirA system was 
utilised. This method was used to identify candidate proteins that are near to or 
interact with human Lamin A, a well characterised component of the nuclear 
envelope as proof of concept (Roux, Kim, Raida, & Burke, 2012). In CLL, isobaric 
labelling and mass spectrometry proteomics was carried out on 14 CLL samples 
and compared to B cells from healthy individuals. A clear signature independent 
of subtype was identified consisting of established proteins of CLL such as CD5, 
BCL2, ROR1 and CD23 overexpression as well as PIGR, CKAP4, CLEC17A 
some of which are involved in the BCR signalling (Johnston et al., 2018). In 
addition, proteomics analysis was used to analyse both M-CLL and UM-CLL. 
PCA analysis indicated significant differences in these two CLL subtypes. 
Specifically, increased levels of F actin capping protein B subunit, 14-3-3 B 
protein and laminin binding precursor were observed in the M-CLL compared to 
UM-CLL. Also nucleophosmin, a cellular protein implicated in mRNA transport, 
chromatin remodelling, apoptosis and genome stability was present in M-CLL 





5.1.1   Generation of ZAP70 expressing B cell lines 
To investigate specific interacting partners of ZAP70, B cell lines BJAB (GCB 
DLBCL), HBL1 (ABC DLBCL) and RAJI (Burkitt’s lymphoma) that contains the 
BirA ligase described earlier with ectopic expression of ZAP70 were generated. 
These cell lines had minimal endogenous ZAP70.  Namalwa cells/inducible 
MEC1 Tet on/off ZAP70 cells were used as a positive control for the ZAP70 
western blot assay as seen in Figure 19A. In addition, RNAseq data from Dr 
Hodson’s lab (not shown) confirmed low endogenous level of ZAP70 in BJAB, 
HBL1 and RAJI cells. To generate the expression system in the cell lines, ZAP70 
was fused to flag tag and expressed using the retroviral transduction system as 
mentioned in the materials and methods section 3.2.6. Since one of the goals of 
this project is to study the role of ZAP70 before and after IgM activation, the 
calcium flux assay was used to confirm that the BCR could be activated in the 
selected cell lines (Figure 19B). The results confirmed that the B cell receptor 
could be stimulated upon IgM activation, marked by the significant difference in 
calcium flux in the cells after anti IgM stimulation. This was performed alongside 
ZAP70 positive patient samples as a positive control.  
Following confirmation of minimal endogenous ZAP70 and activatable BCR in 
the parental cell lines, ZAP70 WT and ZAP70 mutant expressing cells were 
generated in BJAB, HBL1 and RAJI cell lines (Figure 19C). Comparing the 
ZAP70 WT and ZAP70 mutant expressing cells, western blots showed an 
increase in ZAP70 protein expression in ZAP70 WT cells compared to ZAP70 
mutant expressing cells (K369A). Consistently, presence of FLAG tag was seen 
in the wild-type and mutant constructs and not present in the empty vector 
construct (Figure 19C). Figure 19D shows BCR signalling of the BJAB empty and 
BJAB ZAP70 Wild-type cells. In the BJAB cells, there is minimal significant 
difference in terms of magnitude of activation between the ZAP70 wild-type and 
empty vector. In addition, Real time PCR was carried out to verify the over 
expression of ZAP70, the cell lines were normalized to GAPDH and fold change 
was relative to the ZAP70 expression level of Namalwa (positive control). It was 
noted that the expression levels of BirA varied significantly between the cell lines, 
with BJAB cells expressing the highest amount and lower expressions seen in 





    Figure 19: Generation of EV, ZAP70 WT and ZAP70 mutant expression 
systems. (A) Endogenous ZAP70 levels in cell lines were verified by western 
blot analysis. Thawed vials of cells were cultured and passaged 3 times prior 
to harvesting. Namalwa was used as positive control and β actin used as 
loading control. (B) BCR activation of parental cell lines confirmed by calcium 
flux assay. (C, E) ZAP70, FLAG tag, BirA expression levels in the EV, WT and 
mutant expressing cells confirmed by western blot (C) and real time PCR (E). 
(D) Calcium flux assay to confirm BCR activation using anti IgM in the EV and 
WT BJAB cells. 
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5.1.2   Mass spectrometry of BJAB cells with ectopic expression of ZAP70  
Due to its high throughput technology coupled with specificity and sensitivity, 
mass spectrometry (MS) has become the choice for protein identification and 
quantification. Here, mass spectrometry coupled with the BirA approach was 
used to efficiently pull down ZAP70. Figure 20A shows the workflow of the mass 
spectrometry pull down experiment on the BJAB cells utilizing the BirA system. 
First, cells with and without IgM activation were cross-linked using 1% 
formaldehyde and further lysed with COIP lysis buffer. From the cell lysis, 50 µl 
from the cytoplasmic fraction was saved as “input”, remaining supernatant was 
incubated with streptavidin dynabeads. Beads bound to ZAP70 were captured 
using magnetic columns and the supernatant was saved as flow through. ZAP70 
bound beads were washed 5 times with ice cold PBS and two final washes with 
ambic solution was carried out. The beads were then submitted for mass 
spectrometry analysis.  Figure 20B shows the principal component analysis on 
the BJAB empty and BJAB wild type in both the inactivated and activated state. 





    
























































































































































































































































































































5.1.3   Efficient pull down of tagged ZAP70 in transfected cells  
Figure 21 shows that ZAP70 was successfully pulled down with minimal 
contamination represented by the absence of β actin in the elute (Figure 21). 
There is minimal ZAP70 present in the flow through in HBL1 and RAJI cells but 
this is absent in BJAB. This protocol was scaled up to purify ZAP70 for mass 
spectrometry to identify partners that interact with ZAP70.  
         
Figure 21: Streptavidin pull down of ZAP70 using BJAB, HBL and RAJI 
cells. Each cell line consists of Empty Vector (EV), ZAP70 WT (WT) and ZAP70      
Mutant (Mut) expressing cells. Western blot shows input, flow through and elute 











































5.1.4   Protein expression changes post ectopic expression of ZAP70 
ZAP70 plays a vital role in BCR signalling and is activated in response to IgM 
treatment. Here, to identify interacting partners of ZAP70 at both steady state and 
activated state, ZAP70 was pulled down from ectopic expressing BJAB cells with 
BirA expression using streptavidin beads. Stringent filtering was applied and 
volcano plots show the differentially up and down regulated proteins in BJAB cells 
under 3 conditions: inactivated (Figure 22A), activated (Figure 22B) and 
comparison between activated and steady state specifically for ZAP70 wild type 
cells (Figure 22C). Positive confirmation of the successful pull down was verified 
by presence of kinases belonging to BCR signalling such as BTK, LYN, CD79a, 
and SYK, with amplified expression levels post IgM activation (Figure 22). The 
results showed 702 proteins upregulated and 761 proteins downregulated in the 
unactivated state. Upon activation, there were 1163 proteins up-regulated and 
354 proteins down-regulated. Specific to ZAP70 WT at the activated state, 1253 
proteins were up-regulated and 1019 proteins were down-regulated (Figure 22)  
75 
 
              
 
Figure 22: Volcano plots showing differentially up and down regulated 
proteins in BJAB ZAP70 WT cells. Unactivated (A), Activated (B) and specific to 
ZAP70 WT in the activated state (C). FDR of 0.05 was applied. Red data points 
indicate significant regulations with up regulation on the right and down regulation 
on the left side of the volcano plot and black data points are not significant. 
Proteins associated in BCR signalling are highlighted in blue.   









































































































Quantitative 2 dimensional fluorescence difference gel electrophoresis was used 
to compare the 2 CLL subtypes before and after IgM activation. Differences 
between unstimulated UM-CLL and M-CLL cells were observed (Perrot et al., 
2011). The study had shown that anti IgM stimulation induces significantly more 
proteomic response in the UM-CLL compared to M-CLL cells. This is consistent 
with the knowledge that UM-CLL cells are more sensitive to anti IgM activation 
compared to M-CLL. Few proteins upregulated after IgM activations are HNRPK 
(role in pre- mRNA processing) and LSP1 (F actin binding cytoskeletal protein) 
(Perrot et al., 2011). 
In the ZAP70 pull down mass spectrometry experiment, data was subjected to 
gene set enrichment analysis (GSEA) that identified transcriptional changes in 
gene sets involved in BCR signalling, migration and ribosomal pathway (Figure 
23A and 23B). Figure 24A, 24B and 24C also shows the heatmap of proteins 
involved in some of the relevant pathways such as KEGG BCR signalling, KEGG 
actin cytoskeleton and KEGG ribosome respectively. As mentioned earlier, 
kinases such as BTK, SYK, and LYN that are known to be relevant in BCR 
signalling in CLL cells were up-regulated in the ZAP70 WT cells. In addition, there 
were proteins related to migration and focal adhesion such as Rac1, Rac2, 
PTPN6, SWAP70, CDC42 present in the ZAP70 wild-type cells specifically post 
IgM activation.  In regards to the ribosome pathway, the majority of the ribosomal 
proteins were upregulated in the ZAP70 WT cells specifically post IgM activation. 
Up-regulation of ribosomal proteins was confirmed as specific by carrying out full 
proteome mass spectrometry followed by GSEA analysis on BJAB ZAP70 WT 








































































































































































































































Figure 24: KEGG pathway analysis. Changes in key proteins involved in BCR 
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Figure 24C: KEGG pathway analysis. Changes in key proteins involved in 
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5.2           RIME/multiplexed Mass spectrometry of CLL patient cells  
 
Mass spectrometry using BJAB cells has confirmed involvement of ZAP70 in BCR 
signalling, as well as its potential role in migration. However, it was still vital to 
explore interacting ZAP70 in CLL patient cells.  In order to understand the physical 
interaction between neighbouring endogenous proteins that define regulation and 
their function, sensitive protein purification and identification of protein complexes      
was necessary. Here, a quantitative multiplexed method was used that integrates 
rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) 
method with isobaric labelling and tribrid mass spectrometry (Papachristou et al., 
2018), which can unveil protein interactors of ZAP70 at steady state and upon IgM 
activation with increased sensitivity. Briefly, ZAP70 positive patient cells, with or 
without IgM activation were double cross-linked (formaldehyde and DSG 
crosslinking as described in the methods section). The cells were then harvested, 
lysed and incubated with ZAP70 antibody overnight. ZAP70 and interacting 
proteins were captured by incubating cells and relevant antibodies with washed 
Protein G beads. Protein G beads were bound to a magnet and used for mass 
spectrometry analysis. Figure 25A shows the schematic of endogenous ZAP70 
pull down using quantitative multiplexed RIME method. Figure 25B shows the 
principal component analysis showing the segregated clustering of ZAP70 proteins 





    






























































































































































































































































































































































































































































































5.2.1   Mass spectrometry of CLL patient cells  
Similar to immunoprecipatation performed with BJAB cells, stringent filtering 
conditions were used to identify proteins expressed. Figure 26A, 26B, 26C shows 
volcano plots of upregulated proteins bound to ZAP70 at steady state (1420 
genes), upon activation (1352 genes) and specific to ZAP70 in the activated state 
(298 genes) respectively.       
 




Figure 26: Patient cells mass spectrometry analysis. Volcano plots showing 
differentially regulated proteins (red), upregulated proteins on the right and down 
regulated proteins on the left in patient cells specific to ZAP70 versus IgG in the 
unactivated(A), activated (B) and specific to ZAP70 in the activated state versus 
steady state (C). Proteins highlighted in blue below to the BCR signalling complex.  
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Figure 27A highlights the results from GSEA analysis, where KEGG B Cell receptor 
signalling showed enrichment of proteins such as SYK, BTK, CARD11, PLCγ2, 
upon activation. Figure 27B shows changes in proteins involved in cell motility and 
Figure 28A once again shows majority of the ribosomal proteins were enriched 
upon IgM activation in ZAP70 positive patient cells as well. To better understand 
the role of ZAP70 in protein synthesis the puromycin analog (OPP) assay was 
used. OPP was fed to ZAP70 positive cultured CLL cells and incorporated into 
proteins during active protein synthesis. My hypothesis is that ZAP70 positive cells 
will have increases protein synthesis compared to ZAP70 negative CLL cells with a 
further increase upon IgM activation. Figure 28B shows results from the OPP 
assay.  IgM activation does not seem to cause an increase in OPP labelling which 
is contrary to CpG treatment in CLL cells.  CpG-ODN is a relatively strong 
stimulating agent for CLL cells and has shown greater OPP labelling compared to 
IgM (Yeomans et al., 2016). A condition including the addition of CpG-ODN2006  







Figure 27: KEGG B cell receptor signalling. Changes in key proteins involved in 
BCR signalling (A) and Actin cytoskeleton (B) in Patient cells with greater than 20% 
endogenous ZAP70 in B cells at both unactivated and activated state. KEGG 
ribosome pathway analysis on patient cells showing striking upregulation of 
ribosomal protein in the ZAP70 immunoprecipitated post IgM activated cells.   
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Figure 28: KEGG ribosomal pathway. Changes in key proteins involved in 
Ribosomal pathway in Patient cells with greater than 20% endogenous ZAP70 in B 
cells at both unactivated and activated state. KEGG ribosome pathway analysis on 
patient cells showing striking upregulation of ribosomal protein in the ZAP70 
immunoprecipitated post IgM activated cells (A) CLL cells treated with immobilized 
IgM or CpG-ODN2006 or left untreated for 24hours before OPP labelling. Graph 
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5.3           Common ZAP70 interactors in BJAB and CLL Patient cells 
 
In order to focus on proteins interacting with ZAP70, results from both ectopically 
expressing ZAP70 BJAB cells and ZAP70 positive patient cells were compared. 
Using the stringent conditions for both BJAB and patient CLL mass spectrometry 
data, comparisons were performed to investigate proteins in common. Figure 29 
shows a Venn diagram of proteins that are expressed preferentially in the BJAB 
ZAP70 WT and CLL patient groups. The criteria used is log2FC>2 and p ≤0.05. 
This highlights 27 proteins found in common consisting of many BCR related 
proteins such as ZAP70, SYK, SWAP70, PLCγ2, CSK, some ribosomal proteins: 
RPS15A, RPS17, RPS20, and RPS19 and proteins related to migratory pathways: 
SWAP70, PTPN6, LCP1 as well.  Figure 30 shows the correlation plot of interacting 
proteins between BJAB and Patient mass spectrometry. Here, data from one 
patient was used to compare to BJAB data. Proteins that fall exactly or closer to the 
straight line shows the strongest correlation and correlation becomes weaker for 
the proteins that become more scattered.         
                   
Figure 29: Venn diagram illustrating the overlap in ZAP70 interacting proteins 
between BJAB cells and CLL patient cells. Stringent filtering criteria of log2FC 
>2 and p ≤ 0.05 was used. Proteins involved in selected pathways are highlighted: 











































Figure 30: Correlation plot of common proteins between BJAB and Patient 
CLL cells. Proteins in common from mass spectrometry analysis between BJAB 
ZAP70 and endogenous ZAP70 in CLL patient cells  
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5.4           CLL Cell Migration  
 
One of the important signatures relating to ZAP70 identified in the BJAB and CLL 
patient mass spectrometry was involving migratory proteins. In CLL cell trafficking, 
homing and interactions between CLL and accessory cells involves various 
chemokines and their receptors secreted by CLL cells or stromal cells. This 
interaction results in CLL chemotaxis into the tissue microenvironment where the 
cells respond to survival and proliferation signals (Davids & Burger, 2013). To 
investigate the role of ZAP70 in migration, I treated ZAP70 positive patient cells 
with 5µM P505-15 and ibrutinib (positive control) and performed a migration assay. 
Both inhibitors resulted in a significant decrease in migration index in response to 
CXCL12, CCL19 and CCL21 (Figure 31).  
                
 
Figure 31: Effect of ZAP70 on CLL cell migration. 
A significant decrease in migration observed after inhibitor treatment in the 
presence of chemokines CXCL12, CCL19 and CCL21 and when cultured with 





















































To specifically determine ZAP70 effect, ZAP70 positive patient cells were 
nucleofected and on day 6 used for the migration assay. Comparing siZAP70 when 
normalised to siNSC showed a reduction (p=0.0552) in the presence of CCL19, 
and a non significant change in the presence of CCL21 (Figure 32A).  
Similarly to varying endogenous ZAP70 expression levels among patient cells, 
knockdown efficiency differs as well. Figure 32B shows the correlation between 
ZAP70 knockdown efficiency and CLL cell migration index. Increase in ZAP70 
levels showed increased CLL cell migration.       
 
 
Figure 32a: siZAP70 reduces migration index. Changes in migration index 
comparing siZAP70 and siNSC cells in the presence of CCL19 and CCL21. 
Migration index was calculated as the number of cells transmigrating with 





Figure 32b: Correlation between ZAP70 expression and migration in siRNA 
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6. Results:  Role of ZAP70 in DNA Damage in CLL Cells 
 
6.1           Formation of γH2AX foci  
6.1.1   P505-15 increases formation of γH2AX foci  
As mentioned earlier, CLL is a malignancy with chromosomal aberrations. DNA 
damage and alterations of the DDR are features of genetic instability common in 
CLL (Popp et al., 2017). Furthermore, DNA damage driver mutations were found in 
higher proportions in the UM-CLL compared to only 3 driver mutations 9 MYD88, 
CHD2, and del13q found in the M-CLL (Landau et al., 2015). In 2006, it was shown 
that in CpG stimulated CLL cells, there was a correlation (p=0.034) between UM-
CLL and unbalanced translocations (Dicker, Schnittger, Haferlach, Kern, & Schoch, 
2006; Haferlach, Dicker, Schnittger, Kern, & Haferlach, 2007). Comprehensive 
genetic characterization of CLL confirmed that del11q is overrepresented in UM-
CLL. In addition 6qdel, 17pdel and trisomy 12 as the sole abnormality were 
significantly more frequent in UM-CLL patients with p=0.0001,0.003 and 0.015) 
respectively (Haferlach et al., 2007).  Specifically, unpublished data from the 
Ringshausen lab suggest that ZAP70 is present and very mobile in the nucleus of 
CLL cells. My hypothesis is that in ZAP70 positive patients cells, higher levels of 
phospho gamma H2AX foci are expected compared to ZAP70 negative patient 
cells.  
To investigate the role of ZAP70 in DNA damage, CLL patient cells were irradiated 
with 4Gy and immunofluorescence staining was carried out to assess γH2AX foci 
formation. This is representative of greater than 3 patients used for the study. Upon 
4Gy irradiation, formation of γH2AX foci can be seen which is absent in the IgG 






Figure 33: Immunostaining of γH2AX in CLL patient cells after 4Gy 
irradiation.  
 
Figure 34 shows the effect of KU55933 (ATM inhibitor: used as positive control) 
and P505-15. Foci formation is reduced in the presence of 10µM KU55933 and 
γH2AX foci observed when 1µM of KU55933. Furthermore, in the presence of 5µM 
of P505-15, there is increased intensity of γH2AX foci compared to cells treated 











Figure 34: Effect of P505-15 on formation of γH2AX foci. Immunostaining of 
γH2AX in patient cells treated with KU55593 (ATM inhibitor) and P505-15 at two 
concentrations followed by 4Gy irradiation.  
 
 
6.2           P505-15 increases double stranded DNA breaks (Comet assay)  
 
To further quantify the extent of DNA damage upon P505-15 inhibition, the COMET 
assay was carried out to measure DNA strand breaks in cells. Inhibitor treatment 
was carried out for 1 hour followed by irradiation (4Gy). Immunofluorescence 
results showed increased tail length (DNA migrating) at 5µM compared to 0.5µM of 

























Figure 35: Effect of reduced ZAP70 kinase activity on double stranded DNA 
breaks upon irradiation. The comet assay of patient CLL cells treated with either 
5uM (top image) or 0.5uM (bottom image) P505-15 after 4Gy irradiation, 
representative images are shown (A). The quantification of the comet assay (n=20) 
(B).       
 
6.3           P505-15 causes further decrease in cell viability post DNA 
damage  
 
In order to investigate the effect of P505-15 inhibition post chemotherapy or 
irradiation, CLL cells from ZAP70 positive samples were treated with P505-15 
inhibitor at 5µM and 0.5µM concentrations followed by either bendamustine at 
20µM/10µM (Figure 36A) or 4Gy irradiation (Figure 36B). Upon comparing 
untreated cells to bendamustine treatment, there is a significant decrease in live 
cells at both concentrations of bendamustine. In the presence of high concentration 
of P505-15 inhibitor, there is a significant decrease in cell viability and non-
significant change at the lower concentration of P505-15 inhibitor. Inhibitors alone 
(coloured in green) show the baseline effect of inhibitors on CLL cells (Figure 36A). 
Figure 36 B on the other hand shows effect of P505-15 post 4Gy of radiation. Here, 
there is again a significant dose dependent change in cell viability. 
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Figure 36: Reduction in cell viability in CLL cells treated with P505-15 prior to 
irradiation/chemotherapy. Cell viability of CLL cells treated with P505-15 followed 
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6.4               Cell viability is unaffected post ZAP70 siRNA knockdown 
 
To investigate if the results seen above with inhibitor can be replicated using 
ZAP70 knockdown, ZAP70 siRNA and NSC nucleofected cells were used. On day 
6 post nucleofection, cells were treated with Bendamustine (10µM) or irradiated 
(4Gy), decrease in viability was observed comparing control (non transfected) cells. 
However, no significant changes were observed when comparing the siZAP70 to 
siNSC, similar results were observed with irradiation experiments as well (Figure 
37A and B).     
              
 
Figure 37: ZAP70 knockdown does not affect CLL cell viability. Cell viability of 
siRNA (ZAP70 and NSC) treated CLL cells followed by Bendamustine (A) or 4Gy 
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7.1           Role of ZAP70 in B CLL  
 
Of the many prognostic markers of CLL, specifically, ZAP70 expression is a very 
reliable surrogate marker for the distinction between the Ig-mutated and Ig-
unmutated CLL subtypes and ZAP70 status can be easily determined using flow 
cytometry. In 2004, it was shown that UM IgHV is strongly associated with the 
expression of ZAP70, ZAP70 is a stronger predictor of the need for treatment in B-
cell CLL with low levels of ZAP70 being associated with better prognosis of CLL 
(Rassenti et al., 2004). Possible explanations for the effect on prognosis can be 
inferred from research showing that introducing ZAP70 ectopically into ZAP70 
negative CLL cells, enhanced expression of NF-κB target genes such as IL1B, IL6, 
and IL8 upon BCR stimulation possibly by an IKK dependent mechanism, and NF-
κB pathway inhibitors have been explored as novel therapeutic approaches for the 
treatment of CLL (Lopez-Guerra & Colomer, 2010; Pede et al., 2013). Therefore, 
suggesting that ZAP70 acts directly as an amplifier of BCR signalling in CLL, 
resulting in poorer prognosis. Another explanation for the difference in prognosis 
involves the BCL-2 family of apoptosis regulating proteins in CLL, hence why CLL 
is referred to as a disorder with failed apoptosis (decreased death). My aim in this 
project was to investigate the role of ZAP70 in CLL with particular focus on BCR 
signalling, apoptosis, migration and proliferation whilst adding on to the existing 
knowledge.           
Here, I assessed the functional role of ZAP70 by using P505-15. P505-15 is a 
small molecule dual inhibitor of SYK/ZAP70, which has low nanomolar potency  
(IC50=50%). ZAP70 positive CLL cells were treated with two concentrations of 
P505-15 (5µM and 0.5µM) and BTK inhibitor: Ibrutinib (used as positive control) 
and BCR signalling was assessed by calcium flux assay. Significant decrease in 
peak fluorescent intensity using both 5µm and 0.5µM of P505-15 was observed 
(Figure 12). In addition, a decrease in peak fluorescent intensity was seen with 
Ibrutinib, which abrogates signalling downstream of BTK. Alongside P505-15 
inhibitor studies, ZAP70 siRNA knockdown assays were carried out. This was done 
to disentangle the effect of SYK from ZAP70 and minimize off target effects on 
other kinases. The advantage of this approach is individual patients with normal 
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versus decreased ZAP70 expression can be used to determine changes in 
signalling or cell survival keeping other factors constant within the same patient. 
Here I have successfully shown that ZAP70 siRNA significantly lowers ZAP70 
expression with minimal changes in SYK expression (Figure 15). Using this 
knockdown system, calcium flux assays were carried out to assess BCR signalling, 
and apoptosis assays to understand cell survival in ZAP70 siRNA knockdown cells 
were done. Results obtained here do not show a significant decrease in calcium 
mobilization when comparing ZAP70 siRNA and non specific control siRNA (Figure 
16). The absence of significant change between siZAP70 and siNSC could be due 
to the lack of complete loss of ZAP70, as siRNA is a transient knockdown that does 
not have full efficiency. I observed that siRNA efficiency varied across patient cells 
with knockdown ranging between 50%-80% of ZAP70 expression. The stability of 
remaining ZAP70 proteins post knockdown could potentially be masking the effect 
of knockdown in the BCR signalling and proliferation assays. Lastly, papers have 
suggested that ZAP70 acts to enhance the signalling capacity of the BCR complex 
in B cell CLL and is not essential for BCR signalling (Chen et al., 2002), so 
therefore a lack of a difference could suggest increased activity of SYK to reduce 
effect of lowered ZAP70 expression.  This data contradicts results shown by Chen 
et al (2005), whereby post IgM ligations, ZAP70+ CLL cells had higher calcium flux 
than did ZAP70 negative CLL cells. The discrepancy between data presented in 
this thesis and published data in my opinion is due to the different experimental 
systems used which factors in varying levels of ZAP70 in patient and arbitrary 
cutoff of 20% that defines ZAP70 positive and negative B cells.         
The knock down approach was also used to assess the effect on AKT 
phosphorylation. In my data, upon ZAP70 knockdown there was an increase in 
pAKT post IgM activation (Figure 17b), which was contrary to my hypothesis. This 
is also contrary to the findings from studies that used BJAB cells transfected with 
ZAP70. It was previously shown that BJAB cells with ZAP70 expression had 
stronger and prolonged activation of SYK, ERK, and AKT after BCR stimulation 
(Stefania Gobessi et al., 2007). This discrepancy in increase of phospho AKT 
observed in ZAP70 knockdown cells could be due to use of immobilised IgM 
activation rather than soluble IgM. Studies have found that ligation of the BCR with 
sol-IgM induced incomplete responses in CLL cells resulting in transient 
phosphorylation of ERK, and AKT. On the other hand stimulation with immobolised 
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IgM elicited a more complete BCR signal characterised by prolonged 
phosphorylation of ERK and AKT, indicating persistent signalling (Petlickovski et 
al., 2005).         
I further assessed CLL cell survival of ZAP70 positive CLL in the presence/absence 
of soluble anti IgM ligation cells using an Annexin V apoptosis assay. At 24 hours, I 
observed a significant decrease in cell viability using 5µM of P505-15 in the 
absence of IgM and a non-significant decrease upon IgM activation (Figure 13). 
The differences seen with/without IgM supports the data from Hacken et al, in 2015 
that reported that surface IgM is higher in UM–CLL and resulted in increased CLL 
viabililty compared to IgD activation (Hacken et al., 2015). This survival is 
characterised by caspase inhibition, induction of NF-kB and expression of 
antiapoptotic molecules (Bcl-2, Mcl-1) (Bernal et al., 2001) However, overall there 
is a significant increase in apoptosis in the UM-CLL compared to M-CLL cells 
(Coscia et al., 2011). Annexin V data at 48hrs using P505-15 shows a decrease in 
viable cell numbers at both concentrations of P505-15, with a greater significance 
in the absence of IgM ligation compared to IgM activation (Figure 13), again 
supporting earlier findings of IgM preventing apoptosis of B CLL cells. Therefore, 
these results suggest that P505-15 treatment for 48 hours reduces B CLL cell 
viability, however extent of apoptosis can be lowered with IgM ligation.        
Lastly, in the context of proliferation, similar to calcium flux and cell survival, P505-
15 shows a similar effect on CLL cell proliferation measured by carboxyfluorescein 
succinimidyl ester (CFSE) incorporation. ZAP70 positive CLL cells treated with 
varying concentration of P505-15 show a dose dependent decrease in proliferation 
when co-cultured with EL08 expressing CD40L+IL21 with similar levels of decrease 
in proliferation seen with Ibrutinib treatment (Figure 14). Studies have shown that 
CD40 ligation in CLL B cells is a strong stimulus to induce NF-κB signalling and 
survival (Hömig-Hölzel et al., 2008). In addition, my data supports the findings 
made by Schleiss et al, where they showed that ZAP70 positive CLL cells showed 
a proliferative advantage associated with increased phosphorylation of ZAP70/SYK 
and STAT 6 with a further increase upon TLR9 activation (Schleiss et al., 2019).       
All of the above results suggest that ZAP70/SYK inhibition using P505-15 plays a 
direct role in CLL cell BCR signalling, proliferation and cell survival. Therefore to 
conclude, I have shown that P505-15 treatment, in the presence of IgM ligation, 
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results in a significant decrease in BCR signalling, cell survival and proliferation of 
CLL cells suggesting a vital role of ZAP70/SYK in these processes.       
 
7.2           ZAP70 proteomics  
      
Signalling via BCR plays an important pathogenic role in CLL. Within the CLL 
context, ZAP70, a negative prognostic factor, structurally homologous to SYK plays 
an analogous role in BCR signalling. A mass spectrometry based 
phosphoproteomic study comparing quantitative differences in the temporal 
dynamics of phosphorylation in simulated and unstimulated T cells, in both 
activated and unactivated T cells, with/without ZAP70 catalytic activity has been 
carried out. The results showed that kinase activity of ZAP70 stimulates a negative 
feedback pathway that targets LCK and controls the phosphorylation of ITAMS as 
well as downstream targets of CD3 and ζ chain components (Sjölin-Goodfellow et 
al., 2015). In my project, my aim was to understand protein interactors of ZAP70 in 
BJAB cells (B cell line) as well as in patient CLL cells. Mass spectrometry was used 
as it offers ways to dissect information about the vastly complicated protein 
interactions happening in cells.       
CLL cells derived from patients can be extremely difficult to culture/propagate in 
vitro due to rapid apoptosis (maybe suggesting an advantageous in vivo 
microenvironment requirement for survival) thereby hindering long term studies 
including knockdown or over expression experiments to be carried out. I explored 
the use of B-cell lines with minimal endogenous ZAP70 to study ZAP70 interactions 
with other proteins.  Here, I have ectopically introduced ZAP70 to try to answer the 
questions listed on the aims of my project section. So far 3 B-cell lines (BJAB, 
HBL1 and Raji) that have minimal endogenous ZAP70 expression (RNA seq by Dr. 
Daniel Hodson) have been identified. I have also shown that BCR in these cells 
can be activated with IgM at varying levels, this was confirmed by calcium flux 
assays (Figure 19B). The cell lines showed varying levels of activation, which could 
be due to the B cell subtype (activated B cell versus germinal centre B cell).  In my 
experiments, comparing intracellular calcium in the empty vector control to the 
ZAP70 wild-type showed no significant differences (Figure 19D). However, 
previous studies undertaken by Chen et al, 2008 had shown increased intracellular 
102 
 
calcium in the adenovirus ZAP70 wild-type or ZAP70 KA369 expression system 
transduced into patient CLL cells compared to mock. This disparity could be due to 
differences in signalling efficiency between patient cells with endogenous level of 
protein versus cell lines with ectopic expression of protein.       
For mass spectrometry, I utilized the in vivo biotinylation method.  This method 
exploits the use of Escherichia coli biotin holoenzyme synthetase (BirA) that is 
known to perform highly selective, specific and rapid biotinylation of the fused 
protein (Fairhead & Howarth, 2015). Biotin-streptavidin interaction is one of the 
most strongest non covalent bonds known in biology, making it extremely 
advantageous for purification of the protein of interest (Kim, Cantor, Orkin, & Wang, 
2009). In this study, there were varying levels of BirA in each of the cell lines, with 
BJAB cells showing the highest BirA expression (Figure 19C). A possible reason 
for this could be varying efficiency of transducing the BirA into the cell lines. 
Furthermore, since BirA is an active biotin ligase, low, medium and high BirA 
expressing cells all signify efficient biotinylation of the flag biotin tagged gene 
product (J. Wang, Cantor, & Orkin, 2009).       
Here, I have shown that ZAP70 can be successfully pulled down with minimal 
contamination (Figure 21). It was noted that BJAB BirA cells resulted in higher 
levels of purified ZAP70 compared to the other two cell lines, this could be due to 
the varying BirA expression in each of the cell lines as mentioned earlier. For this 
reason, mass spectrometry was carried out on BJAB cells in the first instance.  This 
mass spectrometry approach successfully unveiled ZAP70 interacting protein 
partners and allowed the study of the interaction of ZAP70 with the BCR complex 
as a whole. Some of the main highlights from the mass spectrometry results were 
the presence of known proteins involved in the BCR signalling, giving us positive 
confirmation that our mass spectrometry approach worked in pulling down ZAP70 
and its interacting partners. GSEA analysis on the ZAP70 versus EV at the 
unactivated, activated and specific to ZAP70 (activated) state resulted in novel 
signatures relating to migration and ribosome biosynthesis (Figures 23-24).  
After the successful pull down of ZAP70 from BJAB ZAP70WT cells, I explored 
ways to pull down endogenous ZAP70 from CLL ZAP70 positive cells. After trying 
various methods, the most specific and efficient pull down of endogenous ZAP70 
was achieved using the qPLEX-RIME (quantitative multiplexed method in 
combination with rapid immunoprecipitation mass spectrometry of endogenous 
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method) (Papachristou et al., 2018). This method employs a two-step fixation 
procedure using disuccinimidyl glutarate (DSG) and formaldehyde (FA) to capture 
transient interactions efficiently.  
When comparing ZAP70 pull down results from BJAB and patient cells, similar 
signatures were observed. In both BJAB and primary cells, there was a striking 
collection of ribosomal proteins interacting with ZAP70 upon activation. Previous 
studies reported reduced ribosomal activity in CLL patients, which correlated with a 
reduction in rRNA maturation in CLL. However, a study using polysome profiling 
coupled to microarray analysis examined the translatome of a panel of peripheral 
blood B cells isolated from 34 CLL patients identified a ribosome related signature 
in CLL patients with mRNAs encoding for ribosomal proteins and factors that 
modify ribosomal RNA (Sbarrato et al., 2016). My data suggest that upon IgM 
activation, ZAP70 has a direct role in the ribosomal complex. It could be that 
tyrosine phosphorylation of ribosomal proteins is a way of regulating translation. To 
investigate changes in protein synthesis, the OPP assay was carried out. It was 
seen that ZAP70 positive CLL patient cells showed no significant change upon IgM 
activation, in contrast a significant increase was observed in the presence of CpG.  
Another trend observed in both the BJAB and patient mass spec was the collection 
of proteins involved in cell motility. Specifically, there were proteins involved in 
migration and focal adhesion: LCP1, SWAP70, PTPN6, RAC1, SHP1.  Some of 
these proteins showed upregulation upon activation in the BJAB cells. In CLL, cells 
circulate freely in the peripheral blood but transmigrate to sites such as bone 
marrow and lymph nodes that provide anti-apoptosis and pro survival signals due 
to chemokine gradients supplied by stromal cells. Significant decrease in the 
migration index of CLL cells treated with P505-15 and Ibrutinib was observed 
(Figure 31). This data is consistent with findings that R406 abrogated both CLL cell 
survival and migration (Quiroga et al., 2009). In order to determine the specific role 
of ZAP70 in migration, I carried out ZAP70 siRNA knockdown followed by migration 
assays in the presence of CCL19 and CCL21. My results showed a decreasing 
trend in migration towards CCL19 but not CCL21 in the siZAP70 cells compared to 
siNSC. In addition, there was positive correlation achieved between ZAP70 
expression (based on efficiency of siRNA) and migration index. This data in 
combination with results published by Calpe et al (2013) suggest that ZAP70 could 
play a role in chemokine receptor CCR7 upregulation (ERK1/2 dependent) leading 
104 
 
to increased migration in the presence of CCL19. The “trend” in decrease in 
migration index instead of significant decrease could be due to the extensive length 
of days of cells in culture to achieve knockdown hence affecting cell viability and 
responsiveness of cells to chemokines.  
7.3           Effect of ZAP70 in DNA Damage in CLL 
 
CLL pathogenesis is greatly influenced by alterations in DNA damage response 
(DDR). CD19+ cells in CLL patients have increased numbers of γH2AX foci, a 
marker of DNA double strand breaks, compared to CD19+ cells in MBL 
(monoclonal B-cell Lymphocytosis) patients and healthy individuals (Popp et al., 
2019). MBL is a premalignant stage of CLL and mechanisms of genetic instability 
are involved in the transformation of MBL to CLL. Popp et al also stated that within 
the CLL subtypes, UM-CLL cells have slightly higher γH2AX foci levels compared 
to M-CLL but this difference was not significant.  Here, I show that P505-15 
treatment results in increased formation of γH2AX foci (Figure 34), which correlated 
with my results from the COMET assay, which showed increased DNA damage tail 
length using higher concentrations of P505-15 (Figure 35).  Therefore suggesting 
that presence of ZAP70 in CLL is protecting cells from DNA damage. This was 
contrary to findings from Popp et al, where upon comparing CD38-, CD38+, 
ZAP70- and ZAP70 + CLL samples, all groups had similar γH2AX levels (minor 
differences between these groups were not significant, p=0.6456). A possible 
explanation for the difference in results could be the variability in patient samples. 
Here, since ZAP70 is a protein kinase, it can be suggested that ZAP70 could 
operate as an epigenetic regulator similar to role of nuclear JAK2 (Dawson et al., 
2009).  
In addition, P505-15 treatment prior to irradiation or bendamustine treatment 
resulted in dose dependent significant decrease in cell viability (Figure 36). This 
decrease was not due to the inhibitor and inhibitor alone resulted in greater 
viability. However, comparing siZAP70 to siNSC, this change was not observed 





8. Conclusion & Future work 
 
My research has shown that inhibition of kinase activity of ZAP70/SYK using P505-
15 decreases BCR signalling, survival as well as proliferation. However, this was 
not observed in cells treated with ZAP70 siRNA. Secondly, mass spectrometry 
results in both BJAB cells with ectopic expression of ZAP70 and endogenous 
ZAP70 in ZAP70 positive CLL cells confirm that ZAP70 plays a vital role in BCR 
signalling but interestingly, my data also suggest that ZAP70 plays an important 
role in CLL cell migration and protects CLL cells from DNA damage as well as 
show a striking role of ZAP70 in ribosomal biosynthesis. These findings are 
relevant not only to CLL but also to other B cell malignancies. 
Overall, it is clear that results from my inhibitor studies are contradicting with the 
knockdown approach due to reasons already mentioned above. Specifically, the 
inhibitor targets both SYK and ZAP70 . A specific inhibitor that targets only ZAP70 
would be recommended. Future work should be aimed at addressing some of the 
shortcomings of the current approaches.  As an alternative approach to siRNA, 
CRISPR knockout of ZAP70 in CLL cells should be explored. This method should 
be able to eliminate ZAP70 at the DNA level and provide more consistent absence 
of ZAP70 in CLL cells. However, as stated previously, CLL cells are different to 
grow and proliferate in vitro, which would be a further challenge for CRISPR 
knockout.       
Another factor contributing to the discrepancy in the results between the inhibitor 
and knockdown studies is due to the masking effect of SYK described earlier. One 
suggestion would be to use siRNA against both ZAP70 as well as SYK and 
investigate changes in BCR signalling, survival and proliferation. Alongside, it will 
be interesting to unravel knockdown effects of SYK only and a comparison 
performed with ZAP70 knockdown. This should provide insight to whether ZAP70 
efficiency increases in the absence of SYK in B CLL. A siRNA or CRISPR  
approach would be advisable rather than assessing in overexpression system or 
comparison between ZAP70 positive and negative patient cells.  
Also, as an alternative to the migration assay used, another system that provides a 
chemokine gradient to support migration should be researched. In addition, a role 
of F actin and adhesion proteins should be explored in B CLL cells lacking ZAP70 
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expression as migration in CLL cells seems to be dependent on ZAP70. Finally, to 
address the ribosomal signature observed, it would be worth carrying out polysome 
profiling to investigate changes in CLL cells due to levels of ZAP70 as well as upon 
IgM activation. Finally,  RNA seq experiments on knockdown / CRISPR cells would 
provide insight into gene expression patterns at both steady state as well as upon 
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